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General introduction 
Epidemiology 
Traumatic brain injury (TBI) is a major cause of long-term disability and a 
significant health-care and socioeconomic problem worldwide (1). Social 
costs in terms of years of potential life lost, as well as indirect costs such as 
lost productivity, result in a high burden on society (2). Country based 
incidence estimates range from 108 to 332 hospital admissions per 100,000 
citizens per year (3). According to the World Health Organization, TBI will 
exceed many diseases as the leading cause of death and disability by the 
year 2020. It has been estimated that, worldwide, TBI affects over 10 million 
people annually (4). Currently, the frequency of brain injury is higher than that 
of any other disease (5). TBI affects all age groups and both genders, in 
particular young men. 
It is a heterogeneous disorder with respect to cause, pathology, 
severity and prognosis. Therefore, it is hard to predict expected outcome for 
individual patients (6). Consequences of TBI are significant: more than half of 
the survivors are moderately or severely disabled one year after injury (4). 
Apart from permanent physical disabilities, TBI can be recognized as a 
chronic process associated with a number of non-reversible pathological 
conditions. Increased incidences of seizures, sleep disorders, 
neurodegenerative diseases, neuroendocrine dysregulation, psychiatric 
diseases, sexual dysfunction, bladder and bowel incontinence, and systemic 
metabolic dysregulation may arise and/or persist for months to years post-
injury (7). Despite major progress in understanding the pathophysiological 
sequels of TBI during the last decades, a number of unanswered questions 
still remain.  
 
Pathophysiology 
Immediately after the brain sustains an injury, a biochemical, metabolic and 
circulatory cascade develops. These different pathophysiological 
mechanisms themselves can cause secondary damage, in addition to the 
primary damage caused by the injury itself (7). Subsequently, an acute 
neuroinflammatory response evolves, in which the brain is even more 
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susceptible to the effects of systemic insults such as hypotension, hypoxia, 
hyperthermia, metabolic derangements and pyrexia, all characterized by a 
massive release of inflammatory cytokines, chemokines and adhesion 
molecules (8-10). 
Two essential cytokines in the cytotoxic pathways following TBI are 
interleukin (IL)-1 ß and IL-6. IL-1 β elicits biological responses in a large 
number of cell types and mediates various metabolic functions of the acute 
phase response. Expression of the highly pleotropic cytokine IL-6 has been 
shown to possess both pro- and anti-inflammatory properties and could be of 
critically diagnostic value in determining whether the brain responds in a pro- 
or anti-inflammatory manner (11). A prominent role in initiating and continuing 
this posttraumatic neuroinflammatory cascade is played by microglia, the 
resident macrophages of the brain. 
 
Activated microglia 
In the 1920s, Pio del Rio-Hortega, a Spanish neuroanatomist, conducted the 
first detailed microscopic examination of a, by then, newly discovered cell 
type, postulated as “microglia” (12, 13). For what eventually turned out to be 
a key player in neuroinflammation, it took more than 60 years thereafter 
before microglia, representing one third of the major population of glia cells, 
received renewed interest. It was during the 1980s that modernized 
histological techniques and immunohistochemical methods enabled 
visualisation of microglia in situ (14). Since then, expeditious research in this 
field has led to the knowledge that activated microglia play a crucial role in 
which the central nervous system (CNS) interacts with the immune system in 
brain trauma and disease. 
Even minor disturbances in the CNS homeostasis after trauma can 
promptly lead to microglia activation (15, 16). When activated, microglia 
display functional plasticity, characterized by changes in cell morphology, cell 
number, cell surface receptor expression, and production of growth factors 
and cytokines. Activated microglia can carry out both neurotrophic and 
neurotoxic functions (17). Probably the type of signal emitted by a neuron in 
distress determines the starting of an endogenous auto-protective 
mechanism, including the production of heat shock proteins, anti-
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inflammatory cytokines and anti-oxidants, in order to rescue the cell (18). In 
case of irreversible damage, a more harm-causing mechanism is initiated in 
which activated microglia synthesize inflammatory cytokines, chemokines 
and complement activation proteins. Moreover, expression of specific 
receptors of these immune mediators by activated microglia will inevitably 
lead to programmed cell destruction (19-21). 
So far, the dual and opposing role of activated microglia under 
pathophysiological conditions, promoting repair of brain damage on the one 
hand and causing additional brain injury on the other, has not been 
elucidated yet. In living brain, microglia activation can nowadays be 
visualized and quantified using positron emission tomography (PET).  
 
Positron emission tomography 
PET is an imaging modality used to investigate metabolic, biochemical, 
functional and molecular activity. Patients are given a short-lived 
radiopharmaceutical, also called a radionuclide, produced by a cyclotron. 
Positrons emitted from the radionuclide encounter electrons in the patient's 
body and produce high energy photons (gamma rays), which can then be 
traced by radiation detectors surrounding the patient. Sophisticated 
reconstruction algorithms make it possible to obtain quantitative accurate 
images of the distribution of radioactivity (22). 
The isoquinoline (R)-[11C]PK11195, a well-characterized and widely 
used radioligand in quantification of microglia activation in CNS disease, 
binds to the translocator protein (TSPO), an 18 kDa hydrophobic outer 
mitochondrial membrane protein. In response to CNS damage, a dramatic 
increase in TSPO levels can be found. This finding has led to the proposed 
use of TSPO expression as a marker of brain injury and repair (23). 
Quantification and visualization of TSPO as a measure of microglia 
activation using (R)-[11C]PK11195 PET is thus of potential use in clarifying 
the complex interaction between factors affecting initiation and maintenance 
of microglia activation and inflammatory cytokines. In the light of the fact that 
only a few centres have a clinical PET facility adequately equipped for 
critically ill patients, PET can be seen as a supplement to other devices of 
neuromonitoring in TBI. 
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Cerebral microdialysis 
One technique to monitor various biochemical processes occurring in the 
brain parenchyma is cerebral microdialysis (24). The principle is based on 
the diffusion of substances from the extracellular fluid (ECF), through a 
semipermeable membrane, into a perfusion fluid in a catheter. This perfusion 
fluid, called a dialysate, can be collected and analysed at the distal end of the 
catheter (25). Although many different substances can be analysed, for 
neuromonitoring the attention is focused on substrates related to changes in 
the glycolytic pathways resulting from secondary ischemic damage (glucose, 
lactate, and pyruvate), on products of cell membrane degradation (glycerol), 
and on substances of excitotoxicity (glutamate, aspartate) (26, 27). Cytokine 
release in the ECF, as a reflection of the neuroinflammatory cascade and 
release of excitatory amino acids (EAA), might be related with ongoing 
activation of microglia. Cerebral microdialysis combined with PET receptor 
studies in an in vivo model of TBI may clarify this relation.  
 
In vivo models of traumatic brain injury 
Clinical trials concerning TBI are complicated and, as a rule, non-conclusive 
due to the heterogeneity of the pathophysiological processes following TBI, 
as well as the heterogeneity of the patient population. Animal models of TBI 
on the other hand, provide a unique opportunity to study pathophysiological 
processes in a standardized manner. Experimental studies, performed in a 
well-equipped laboratory under stable and controlled environmental 
conditions, will minimize variability with regard to the mechanism of injury, 
thereby enabling the study of patterns of pathophysiological responses in a 
specific situation. 
It has shown to be impossible to develop one experimental TBI model, 
which encompasses all pathophysiological entities of TBI. Current in vivo 
models of TBI can be classified into focal and diffuse injury models. 
Depending on the scientific hypothesis, specific characteristics of the in vivo 
TBI model will be required (28). Focal injury includes localized cortical 
contusions and intracerebral hematomas and can be achieved by the 
controlled cortical impact (CCI) injury model and the lateral fluid percussion 
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model (LFP). Acceleration/deceleration forces onto brain tissue cause diffuse 
axonal injury and can be produced by the impact acceleration model and the 
midline fluid percussion model (MFP).  
For our experimental TBI studies, we were interested in severe TBI 
because low injury levels probably do not exhibit sufficient macroscopic and 
microscopic brain damage. In severe TBI by the MFP, high impact forces 
acting on the brainstem result in a high mortality rate of more than 50%. 
Macroscopically, traumatic subarachnoid haemorrhage and in more than 
20% of the cases acute subdural hematoma (ASDH) is seen (29, 30). In FPI, 
as compared with MFP models, greater cortical damage can be produced 
with less direct brainstem compression (31) with cortical and subcortical 
haemorrhage, focal oedema and displacement of midline structures (30). 
In impact acceleration models, a falling weight is applied to an open or 
closed skull. A falling weight on a closed skull causes diffuse brain injury, 
whereas focal brain injury is induced by a falling weight on an open skull. The 
closed impact acceleration model is applicable in producing various degrees 
of neuronal damage, axonal injury and disturbances in microvasculature. 
Degree and extent of TBI is correlated directly with the size of impact of the 
trauma and the resulting acceleration forces applied to the head of the 
rodent. A limitation of impact acceleration models is the relatively high 
occurrence rate of skull fractures, when inducing accelerations severe 
enough to cause concussive brain injury (32, 33). 
In severe TBI using the CCI, ASDH and contusion of the brain stem 
and spinal cord are seen in all lesions produced with an high velocity impact 
(4 m/s) (34). In experienced hands, the CCI is an accurate experimental TBI 
model with a high degree of reproducibility. Independent control of 
mechanical loading parameters makes the CCI a very useful experimental 
tool in studying focal brain injury (35). 
 
Aim and outline of this thesis 
The main purpose of the studies in this thesis is to elaborate microglia 
activation and the neuroinflammatory cascade following TBI. Although a 
significant increase in the knowledge of the pathophysiology of TBI has been 
made, an urgent need to disentangle specific aspects of the posttraumatic 
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neuroinflammatory cascade remains, in order to improve the outcome of this 
category of, often life-long, severely affected patients. We set out to 
determine whether it was possible to detect inflammatory cytokines in the 
ECF using cerebral microdialysis in experimental TBI. Simulation studies for 
both plasma and reference tissue input models were performed to determine 
the reliability of (R)-[11C]PK11195 PET studies in human brain after TBI. The 
final step was to look at the posttraumatic inflammatory response over time, 
using (R)-[11C]PK11195 PET in rat and human brain. 
Within the neuroinflammatory cascade, activated microglia extensively 
produce inflammatory mediators. In chapter 2 we established extraction 
efficiency of two main neuroinflammatory cytokines, i.e. interleukin (IL)-1 ß 
and IL-6, using an in vitro microdialysis-perfusion system. Temporal profiles 
of these cytokines in the ECF of living brain after severe TBI and sham-
operated rats were measured using cerebral microdialysis. It is known that 
after severe TBI, large quantities of EAA are released into the ECF of brain 
tissue. In line with our first study, we explored the acute EAA release in the 
ECF after severe TBI as a reflection of neuroinflammation and correlated 
these findings with microglia activation one and 10 days after injury using 
(R)-[11C]PK11195 PET to explore TSPO expression (chapter 3). In (R)-
[11C]PK11195 PET studies in TBI, a reference tissue was lacking due to the 
blood brain barrier (BBB) disturbances in the acute phase after injury. To 
tackle this problem, methodological considerations in using validated tracer 
kinetic models with both plasma and reference tissue input models for (R)-
[11C]PK11195 PET in TBI was explored in chapter 4. Considering TBI as an 
ongoing global brain disorder, we were interested if and to what extent long 
term microglia activation is present, six months after injury (chapter 5). 
Finally, we analysed (R)-[11C]PK11195 binding in perilesional zones 
surrounding traumatic brain lesions (chapter 6), while these zones are 
susceptible for additional brain damage and probably can make the 
difference in final outcome if protected properly. The main findings in this 
thesis are discussed and criticized in perspective towards recommendations 
for future research in chapter 7. 
 
 CHAPTER 2 
Cerebral microdialysis of Interleukin (IL)-1β and IL-6: 
extraction efficiency and production in the acute 
phase after severe traumatic brain injury in rats 
 
 
 
 
 
 
 
 
 
 
 
Hedy Folkersma, John JP Brevé, Fred JH Tilders, Claudia S Robertson 
W Peter Vandertop 
 
Acta Neurochir 2008 (150) 1277-84 
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Abstract  
Background As a research tool, cerebral microdialysis might be a useful 
technique in monitoring the release of cytokines into the extracellular fluid 
(ECF) following traumatic brain injury (TBI). We established extraction 
efficiency of Interleukin(IL)-1ß and IL-6 by an in vitro microdialysis-perfusion 
system, followed by in vivo determination of the temporal profile of 
extracellular fluid cytokines after severe TBI in rats. 
Methods In vitro experiments using a polyether sulfon (PES) microdialysis 
probe especially developed for recovery of macromolecules such as 
cytokines, were carried out to establish the extraction efficiency of IL-1ß and 
IL-6 from artificial cerebrospinal fluid (CSF) with defined IL-1ß and IL-6 
concentrations. In vivo experiments in which rats were subjected to TBI or 
sham and microdialysis samples were collected from the parietal lobe for 
measurement of cytokines. 
Results The extraction efficiency was maximal 6.05% (range, 5.97–6.13%) 
at 0.5 µl/min and decreased at higher flow rates. Both cytokines were 
detectable in the dialysates. Highest IL-1ß levels were found within 200 min, 
highest IL-6 concentrations were detected at later intervals (200–400 min). 
No differences were found between the TBI and control groups. 
Conclusions Cerebral microdialysis allows measurement of cytokine 
secretion in the ECF of brain tissue in rats. 
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Background 
Traumatic brain injury (TBI) results in an inflammatory cascade, initiated by 
the release of inflammatory cytokines (9, 11, 36-43). The exact contribution 
of these substances to local tissue damage is still not fully understood. 
 Interleukin(IL)-1ß exhibits several actions in the brain, critical for host 
defence against brain injury and disease. This pluripotent, pro-inflammatory 
cytokine participates in a complex network of signalling molecules and seems 
to be one of the most important factors in the propagation and maintenance 
of the inflammatory cascade after TBI, being responsible for enhancing the 
activation of T-cells (11, 36, 44, 45). IL-1 ß belongs to the IL-1 family which 
has three well-known endogenous ligands, two agonists, IL-1α and IL-1 ß, 
and one IL-1 receptor antagonist (46). IL-1 ß is synthesised as a cytosolic 
precursor protein of 31 kDa and after cleavage in the mature 17 kDa form, it 
becomes biologically active (47-49). Microglia, expressing caspase-1, the 
enzyme responsible for cleaving pro-IL-1 ß, has been recognised to be the 
earliest and major source of IL-1. Also, various other endogenous brain cells, 
such as astrocytes, oligodendroglia, neurones, endothelial cells, and 
circulating immune cells, are able to express IL-1 ß (50, 51). At least two 
types of IL-1 receptors are known, type I (IL-1RI) transduces the IL-1 signal 
and is widely expressed, type II (IL-1RII) is found on B cells, neutrophils and 
monocytes and preferentially binds IL-1 ß. IL-1 ß mediates the release of 
multiple pro-inflammatory cytokines, chemokines, prostaglandins, and other 
inflammatory mediators (50, 52). 
The pleotropic cytokine IL-6 mediates both deleterious and beneficial 
effects following TBI (53) and acts in synergy with IL-1 and tumour necrosis 
factor alpha (TNF-α), augmenting the response of immune cells to other 
cytokines (54). It has a molecular weight of 26 kDa and belongs to a 
superfamily of structurally related cytokines with diverse biological properties. 
IL-6 is released in response to IL-1 and TNF-α, and secreted by T cells, 
astrocytes, microglia, and neurones (55). The IL-6 receptor, present on the 
cell surface, consists of an IL-6 binding alpha chain and a signal transducer, 
gp130, which is shared among the receptors for the IL-6 related cytokine 
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subfamily. Interactions of IL-6 with its receptor give rise to profound 
inflammatory cytokine production (56). 
Intracerebral microdialysis is based on the principle of diffusion of 
water-soluble substances across a semipermeable membrane, and clinical 
experience is rapidly increasing in patients with an ischaemic stroke, 
vasospasm-induced ischaemia after subarachnoid haemorrhage and severe 
brain trauma (57). In the extracellular fluid (ECF), liquid found between the 
cells containing proteins and electrolytes, profound disturbances have been 
demonstrated in concentrations of glutamate and aspartate and energy-
related metabolites such as lactate, pyruvate, adenosine, inosine and 
hypoxanthine after brain injury and these changes correlate with the severity 
of the injury (58-64). 
Recovery of cytokines and neurotrophins from the ECF of the brain 
has been reported in patients suffering from severe TBI using cerebral 
microdialysis (65, 66). Although these observations are promising, we 
wondered whether intracerebral implantation of the microdialysis probe alone 
would affect cytokine production in the brain. Using a cerebral microdialysis 
probe, we first studied IL-1ß and IL-6 extraction efficiency in vitro followed by 
subsequent in vivo studies to determine the temporal profile of IL-1ß and IL-6 
release in the ECF after TBI. 
 
Methods 
Throughout this paper we use the term “extraction efficiency” to describe the 
cytokine concentration in the dialysate expressed as a fraction of the cytokine 
concentration in the sample medium (67). 
 
Microdialysis in vitro 
We used a 2 mm length microdialysis polyether sulfon (PES) probe (CMA/12 
14/02 PES CMA/Microdialysis AB Solna, Sweden) with an outer diameter of 
0.5 mm and a molecular weight cut-off of 100 kDa especially developed for 
microdialysis experiments on high molecular weight substances equipped 
with a micro-injection pump and microfraction collector (CMA/102 CMA/142 
CMA/Microdialysis AB Solna, Sweden). The inlet (12 cm) and outlet (7 cm) 
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tubings from the microdialysis probe were connected to a syringe cannula 
and microfraction collector, respectively. The microdialysis perfusion fluid and 
the sample medium (2.5 ml) consisted of artificial cerebrospinal fluid (CSF) 
(Na 147 mmol/L; K 4 mmol/L; Ca 2.3 mmol/L; Cl 156 mmol/L; pH 6.0; 
290 mOsm/L) containing 0.5 mg/ml bovine serum albumin (BSA) fraction V 
(BSA; Sigma-Aldrich Chemie Steinheim, Germany) unless otherwise stated. 
 
Sampling procedures 
For measurements of the extraction efficiency, the microdialysis probe was 
placed in an Eppendorf tube, sealed hermetically containing 2.5 ml of 
sampling medium with one of four different concentrations (2, 10, 50, 
250 ng/ml) of recombinant rat IL-1ß or recombinant rat IL-6 (gift from Dr S 
Poole, NIBSC, Potters Bar, UK). The standard cytokine solutions were 
prepared freshly preceding each in vitro experiment. Sequential dialysate 
samples of 100 μl each were collected in airtight Eppendorf tubes containing 
150 μl High Performance ELISA (HPE)–buffer solution (Central Laboratory of 
the Netherlands Red Cross Blood Transfusion Service, Amsterdam, The 
Netherlands), and stored at −20°C until assayed for rat IL-1ß and rat IL-6. All 
conditions were tested in at least two parallel experiments. To maintain a 
constant environmental temperature, all in vitro experiments were performed 
at 37.0°C in a desiccation stove. 
In one set of experiments, the microdialysis probe remained in the 
sampling medium (cytokine concentration: 50 ng/ml), and the flow rate was 
increased stepwise (0.5–2.0 μl/min) to establish the effect of flow rate on 
extraction efficiency. In another set of experiments, we studied the 
relationship between the cytokine concentrations outside the probe with that 
in the dialysate. Therefore, the flow rate was kept constant (1.0 μl/min) and 
the dialysis probe was transferred at 200 min intervals into sampling medium 
containing increasing concentrations of cytokines (2, 10, 50, and 250 ng/ml). 
In this experiment, sample interval was 100 min. 
To study the temporal relationship between changes in cytokine 
concentration outside the probe versus the dialysate, the probe was placed in 
medium containing 10 or 50 ng/ml IL-1ß or IL-6 for 600 min. Flow rate was 
maintained at 1.0 μl/min and six dialysate samples were collected. 
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Thereafter, the probe was transferred into cytokine free sample medium for 
another 200 min, and two sequential samples of 100 min were collected. 
 
Surgical preparation and controlled cortical impact 
The tail artery was cannulated with a 14G polymer catheter (length 25 mm) 
and connected to a pressure transducer to monitor blood pressure and obtain 
blood gases. The head of the animal was mounted in a stereotactic frame. 
After a midline scalp incision, a craniotomy was performed over the right 
hemisphere extending from the lambda to the bregma and zygomatic arch. In 
six rats, a standard severe controlled cortical impact (CCI) was applied as 
described by Dixon et al. (68). The impactor tip with a diameter of 7 mm was 
adjusted to produce an impact at the centre of the exposed brain with an 
impact velocity of 5 m/s, duration of 130 ms, and a depth of 3 mm. The 
impact velocity of the CCI was monitored with the use of a computer software 
program (LabView for Windows). Sham rats underwent an identical surgical 
procedures but did not undergo a CCI. The microdialysis probe was placed 
stereotactically in the right hemisphere at a depth of 3 mm (co-ordinates: 
−1.5 mm bregma, 3.0 mm lateral), afterwards. After CCI or sham procedure, 
via a small burrhole, an intracranial pressure monitor and brain temperature 
device was placed in the contralateral frontal hemisphere. Subsequently, the 
scalp incision was closed. Animals remained in the stereotactic frame 
throughout the whole experiment. 
 
Microdialysis in vivo 
Twelve adult, male Sprague Dawley rats (300–350 g; Harlan, Indianapolis, 
USA) were accustomed to the laboratory for at least 24 h. They were 
anaesthetised with Isoflurane 5% in a ventilated anaesthesia chamber. After 
endotracheal intubation with a 16-gauge Teflon catheter, the rats were 
mechanically ventilated at a respiratory rate of 80 breaths per minute and 
remained under full anaesthesia during the whole experiment (Isoflurane 2% 
in oxygen 45%). The animals were evaluated every 15 min for level of 
anaesthesia by monitoring the pinch reflex. Rats were either subjected to 
focal TBI (n = 6) or served as controls (n = 6). Directly thereafter, the 
microdialysis probe was inserted to a depth of 3 mm into the penumbra zone 
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of the lesion or normal brain parenchyma (controls) according to the following 
coordinates: −1.5 mm from bregma, 3.0 mm lateral from midsagittal line and 
perfusion was started at a flow rate of 1.0 μl/min. Similar to the in vitro 
experiments, the microdialysis perfusion fluid consisted of artificial CSF 
containing 0.5 mg/ml BSA fraction V. The sampling procedure was started 
30 min after probe insertion. Four sequential dialysate samples were 
collected, at a time interval of 100 min. Animals remained in the stereotactic 
frame throughout the experiment. Body and brain temperatures where kept 
within normal range. At the end of the experiment, the rats were sacrificed by 
decapitation. 
 
Cytokine assays 
IL-1ß and IL-6 concentrations of the medium and dialysates were measured 
using an enzyme-linked immunosorbent assay (ELISA) specific for rat IL-1ß 
and rat IL-6 as described elsewhere in detail (69-71). The detection limit of 
the assay was 10 pg IL-1ß/ml and 50 pg IL-6/ml, respectively. 
 
Statistical analysis 
Data is expressed as mean ± standard deviation. Pearson correlation 
coefficients were used to analyse the correlation between the measured 
cytokine concentration of the medium and cytokine concentration of the 
dialysates obtained. Differences were rated significant at a probability error of 
less than 0.05. The statistical evaluation was carried out using SPSS 9.0 for 
Windows. 
 
Animal ethics 
The research protocol for the in vivo experiments as outlined above was 
reviewed and approved by the Animal Protocol Review Committee at Baylor 
College of Medicine Houston, Texas USA, using the National Institutes of 
Health guidelines for the care and use of laboratory animals. 
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Results 
Microdialysis in vitro 
In vitro microdialysis experiments using dialysis fluid without serum albumin, 
revealed low but detectable concentrations of IL-1ß (6 pg/ml) only in the first 
dialysate sample (50 min). In all subsequent dialysate samples, including the 
wash-out samples, IL-1ß concentrations were below the lower limit of 
detection. Measurements of IL-1ß in the medium itself, showed a substantial 
decrease in IL-1ß concentration (from 3277 to 305 pg/ml) before and after 
dialysis for 200 min. Also, a gradual decrease in concentrations of IL-6 in the 
dialysates was found. Extraction efficiency decreased from 7.07% at the 
beginning of the experiment to 2.24% at 200 min. In both wash out samples, 
IL-6 concentrations were below detection limit (<50 pg/ml). Samples taken 
from the medium at 0 and 200 min, showed a more than 50% decrease in 
cytokine concentration. 
As the disappearance of IL-1ß and IL-6 from the medium may relate to 
non-specific binding to tubing, microdialysis probe, vials etcetera, we added a 
protein coat to the medium and perfusion fluid (0.5 mg/ml BSA). This resulted 
in steady concentrations of cytokines in the medium. Furthermore, extraction 
efficiency at a certain flow rate was found constant during the experiment. 
Therefore, BSA was used in all experiments described. 
Experiments designed to study the relationship between the cytokine 
concentration outside the probe with that in the dialysate revealed a linear 
relationship (r = 0.953, p < 0.05, two tailed) between the cytokine 
concentration in the medium and microdialysis samples over a wide 
concentration range. In these experiments that are carried out at a flow rate 
of 1.0 μl/min, the extraction efficiencies of IL-1ß and IL-6 were 0.82 ± 0.60% 
and 0.75 ± 0.49%, respectively (Figure 1a). 
Experiments in which the flow rate was altered during perfusion 
revealed that increased flow rates resulted in decreasing extraction 
efficiencies (r = −0.746, p < 0.05). For instance, at a flow rate of 0.5 µl/min, the 
mean extraction efficiency was 6.05% (range: 5.97–6.13) and increasing the 
flow rate to 1.0 µl/min decreased the mean extraction efficiency of IL-1ß to 
1.46% (range 0.73–2.89) (Figure 1b). 
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Figure 1. a. Relationship between cytokine concentration in the medium and in the dialysate 
sample. Studies were performed at a flow rate of 1.0 μl/min. Stepwise increase in cytokine 
concentrations in medium result in proportional changes in the dialysate. b. Relationship 
between extraction efficiency and flow rate as determined in vitro. 
 
Microdialysis in vivo 
In three CCI and four control rats, detectable IL-1ß (>1.2 pg/ml) was found in 
one or more dialysate samples. Except for one control rat, in all of these “IL-
1ß responders”, the highest levels IL-1ß were found in the first 100 min 
following insertion of the microdialysis probe (mean: 9.0 ± 9.2 pg/ml). In one 
control rat, the highest ECF IL- ß concentration was found at 200 min. 
Concentrations of IL-1ß were lowest at 300 min following insertion of the 
microdialysis probe (mean: 3.7 ± 2.2 pg/ml). Mean IL-1ß concentrations at 
200 and 400 min was 6.4 ± 6.2 and 4.9 ± 2.6 pg/ml, respectively. No 
significant differences in IL-1ß concentrations were found between CCI and 
control rats (Figure 2a). 
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Figure 2. a. + b. Temporal pattern of cytokines in the rat brain following CCI and control 
conditions. a. extracellular IL-1ß, b. extracellular IL-6. Ordinate shows time interval following 
probe implantation. Connected data points refer to individual rats. 
 
Four CCI and five control rats had detectable IL-6 concentrations 
(>20 pg/ml) in one or more dialysate samples. Except for one CCI rat, all “IL-
6 responders” had the highest IL-6 concentrations (43.8 ± 16.6 pg/ml) at the 
end of the experiment (400 min). One CCI rat had the highest ECF IL-6 
concentrations at 300 min. Furthermore, a gradual increase in IL-6 
concentrations was noted. At 100 min, IL-6 was detectable in only one 
sample (25.6 pg/ml). Mean IL-6 concentrations at 200 and 300 min were 
26.5 ± 1.6 and 38.3 ± 26.8 pg/ml, respectively. No significant differences in 
expressions of IL-6 were found between CCI and sham operated rats (Figure 
2b). 
Six out of seven “IL-1ß responders” were “IL-6 responders” as well 
(n = 6). Four of these belonged to the control group. In one CCI rat, only IL-1ß 
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was detectable in the dialysates. Three rats, of which two belonged to the 
control group, were “IL-6 responders” but IL-1ß was not detectable in any of 
the samples. In two rats, one CCI and one control, both IL-1ß and IL-6 
concentrations were below the detection limit. 
 
Discussion 
In the present study we demonstrated that the extraction efficiency of IL-1ß 
and IL-6 is constant over a wide concentration range of these cytokines, 
using in vitro approaches. Using in vivo microdialysis, we show the temporal 
pattern of cytokine secretion in the brain of rats during the acute phase of 
brain surgery and CCI. 
 
Microdialysis in vitro 
In vitro studies were designed to study extraction efficiency of cytokines, in 
which BSA was added to the microdialysis perfusion fluid and sample 
medium. Serum albumins are often used to saturate non-specific binding 
sites on plastics and other materials, thereby reducing non-specific binding of 
low abundancy proteins, peptides and other materials (72). Indeed, addition 
of BSA to the medium largely prevented cytokine disappearance and 
markedly increased the cytokine concentrations in the samples and improved 
the consistency of the results. At a flow rate of 1.0 µl/min, steady state 
cytokine concentrations were measured within 1.5 h after placement of the 
probe in a cytokine-containing medium. Thus, at this flow rate the present set 
up allows signals outside the microdialysis probe to be detected in the 
dialysate with a delay of approximately 1–1.5 h. 
Appropriate interpretation of the results of cytokine measurements in 
the microdialysis samples requires knowledge on the relationship between 
ECF cytokine concentration and the levels measured in the dialysate. In the 
present study, we demonstrate a fair linear correlation between the cytokine 
concentration as measured in the medium and that in the dialysates over a 
wide concentration range of IL-1ß and IL-6. This indicates that alterations in 
the signal measured in the dialysate can be interpreted as proportional 
changes in the medium outside the membrane i.e. in the ECF. The data 
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further show a mean extraction efficiency of rat IL-1ß and IL-6 of 1.2% and 
0.7%, respectively. 
As expected, the extraction efficiency is affected by the flow rate. As 
shown in the present data, increasing the flow rate results in a non-linear 
decline in extraction recovery. We hypothesise that in addition to flow rate 
dependent sample dilution, increasing the flow rate leads to an increase in 
hydrostatic pressure which may result in a net outflow of dialysate fluid and 
consequently in a non-proportional decline in the apparent diffusion of 
cytokine across the membrane. From this perspective, the flow rate should 
be as low as acceptable to increase cytokine recovery. Given the lower limit 
of sample volume for appropriate sample handling, reduction of the flow rate 
will require increased sample collection time and consequently reduce the 
temporal resolution of alterations in cytokine secretion. Thus, the conditions 
represent a compromise that is largely dictated by the extraction efficacy, the 
lower limit of detection of the cytokines and, temporal resolution required in 
the experiment. 
The zero net flux method as described by Lönnroth et al. is another, 
well known approach to investigate recovery rates of substrates by 
microdialysis. Varying the concentration gradient over the microdialysis 
membrane by gradually increasing the substrate of interest in the perfusion 
fluid, a corresponding change in net influx in the dialysate can be recorded 
(73). 
 
Microdialysis in vivo 
Following on our in vitro experiments, we performed experiments in rats 
either exposed to focal brain injury or sham procedure. The goal of these 
experiments was twofold. First, to explore the feasibility of cytokine extraction 
from the ECF of the brain using cerebral microdialysis. Secondly, to elucidate 
the temporal profile of extracellular IL-1ß and IL-6 in the acute phase after 
TBI. 
Both IL-1ß and IL-6 were detectable in the dialysates in seven and 
nine animals, respectively. Highest expressions of IL-1ß were found in the 
first samples obtained. Given the delay of the signal which is in the present 
setup approximately 60–90 min, it seems that IL-1ß that is present in the first 
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sample is supposed to be secreted short after placement of the dialysis 
probe in healthy or traumatised brain tissue. This observation is in 
accordance with previous studies, which have shown increased expression 
of IL-1ß in the acute phase following TBI (74, 75). IL-1ß is a pluripotent 
cytokine and plays a key role in the inflammatory cascade (11, 76). It has 
been reported that IL-1ß acts as a mediator in the inflammatory response 
and induces the expression of neuroprotectant- and neurotrophic factors in a 
traumatised brain (77). Furthermore, enhanced glial activation is associated 
with increased expression of inflammation-related mRNA’s, including IL-1ß, 
tumor necrosis factor (TNF)-α and, IL-6 (78). 
Most of the early experimental TBI studies measured high levels of 
cytokines in brain homogenates, which include both intracellular and 
extracellular proteins. Raghupathi and colleagues found increased IL-1ß 
levels at one hour after trauma, which remained elevated up to 6 hours (79). 
Experiments from the same group show significantly increased IL-1ß mRNA 
expression one till six hours after TBI (80). Taupin et al. found increased IL-6 
and IL-1 levels, 8 hours after trauma in the ipsilateral cortex. Elevated 
cytokine concentrations were observed up to 18 hours and decreased 
thereafter to basal values (81). As compared to these studies, the lower 
cytokine concentration found in our series using cerebral microdialysis, might 
be due to the lower level of secreted cytokines in the ECF. 
Our findings suggest that release of IL-1ß precedes a gradual 
increase in expression of IL-6. Increased expression of IL-1ß in the acute 
phase after brain injury could be the mediator of the increased production of 
IL-6. The pro-inflammatory cytokine IL-1ß, induces central nervous system 
(CNS) glial cells to produce other cytokines (52). In a study of Knoblach et 
al., significantly elevated IL-1ß were found 4 hours after fluid percussion 
brain injury in the ipsilateral cortex (75). Moreover, Acarin et al. found 
increased expression of IL-1ß and TNF-α followed by cytokine positive cells 
for IL-6 in an adjacent area 2–10 hours after injection of N-methyl-D-
aspartate, producing an excitotoxic lesion in the brain (82). 
In our study, no significant difference in extracellular IL-1ß and IL-6 
concentrations was found between TBI rats and controls. From extensive 
research work done by, amongst others, Feuerstein and co-workers, it is 
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known that inflammatory processes endure for at least several days after 
brain injury (9). In our experiments, the time of measuring cytokines 
(400 min) is probably too short to explore the whole spectrum of the post-
traumatic neuroinflammatory cascade. However, one of the main purposes of 
this pilot study is to explore whether it is possible to measure cytokine 
release in rat brain with the use of microdialysis techniques. In the future, an 
experimental set-up, in which animals are awake and monitored for a longer 
period, will be an interesting follow-up study. 
Fairly frequently, IL-1ß and IL-6 levels were found below the lower 
detection limit in the dialysates. Early microdialysis experiments of 
Benveniste et al., tissue reactions were found adjacent to the microdialysis 
probe. In the first days after insertion, haemorrhage surrounding the probe 
was found occasionally. Late tissue effects consisted of collagen deposits 
and occasional granuloma formation (83). Although the microdialysis probes 
used are designed for studies on high molecular weight substances, pores of 
the membranes could be blocked by blood or brain particles due to traumatic 
alterations of brain tissue, thereby reducing extraction efficiency. If this is the 
case, further slow down of the flow rate in the in vivo experiments will 
possibly increase the cytokine extraction resulting in higher cytokine 
concentrations in the dialysates. Taking the increased sampling time into 
account and adjusting sample frequency, lowering the flow rate or ultimately 
a stop flow experiment would be interesting in long-term microdialysis 
experiments. 
The specific contribution of the surgical procedures, and in particular 
penetration of the microdialysis probe in the brain parenchyma itself, to the 
inflammatory response is an important factor in the interpretation of our 
microdialysis data. Woodroofe et al. showed in their studies that the probe 
itself, without additional trauma, is sufficient to elicit a local immune response 
in the brain with increased IL-1, 2 days after implantation. IL-6 was strongly 
increased early until day 1 and decreased by day 2 (84). Although minimally 
invasive, the microdialysis technique could give rise to a restricted acute 
inflammatory response. If this is the case, the (local) inflammatory cascade 
could lead to haemostatic disturbances in the brain tissue surrounding the 
probe, resulting in changes of concentrations of substrates in the interstitial 
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fluid and thereby influencing the microdialysis results. Therefore, using 
cerebral microdialysis in monitoring metabolic and neurochemical parameters 
as well as mediators of the inflammatory cascade in the ECF of injured brain 
tissue, one has to take into account that local environmental disturbances 
caused by the microdialysis probe itself, might result in temporary alterations 
in substance concentrations. 
 
Conclusions 
Microdialysis allows monitoring of IL-1ß and IL-6 secretion into the damaged 
brain. Addition of a carrier protein to the medium and the perfusion fluid 
markedly enhances the apparent extraction efficiency, thereby facilitating the 
detection of cytokines in microdialysis studies in vivo. Extraction efficiency is 
consistent for at least eight hours for both cytokines tested, independent of 
the cytokine concentration. Extraction efficiency decreases by increasing flow 
rate. Extraction efficiency at higher flow rates is not reliable when using a 
PES membrane with a high molecular weight cut off (100 kDa). 
Our findings further suggest that release of IL-1ß precedes a gradual 
increase in expression of extracellular IL-6. No significant difference was 
found between injured and sham operated rats in expression of extracellular 
Il-1ß and IL-6 indicating that surgical procedures and implantation of the 
microdialysis probe itself may cause cytokine release in the brain. Further 
studies are therefore needed to determine whether cerebral microdialysis for 
monitoring cytokines may be useful in this field of research. 
 Comments 
These are important validation studies, with the new 100 KD microdialysis 
probes, in Vitro, and in vivo. They establish recovery rates of cytokines, the 
best perfusion rates and dialysate composition. Now it remains to be seen if 
microdialysis using these new probes, can elucidate details of the 
pathobiology, of IL1 and IL6 in causes of brain damage, such as TBI, stroke, 
and SAH. 
 
M. Ross Bullock 
University of Miami Miller School of Medicine 
 
I can only emphasise the importance of characterising the microdialysis  
technique to improve its potential applications in neurotrauma as in any other 
pathology. Since the extraction efficiency of cytokines in microdialysates is 
low, new strategies need to be established to maximise its retrieval. It would 
still remain to explain the lack of differences in cytokine concentration 
between TBI and sham animals. 
 
Cristina Morganti-Kossmann 
Monash University 
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Abstract 
Background The aim of the present study was to investigate microglia 
activation over time following traumatic brain injury (TBI) and to relate these 
findings to glutamate release. 
Methods Sequential dynamic (R)-[11C]PK11195 PET scans were performed 
in rats 24 hours before (baseline), and one and ten days after TBI using 
controlled cortical impact, or a sham procedure. Extracellular fluid (ECF) 
glutamate concentrations were measured using cerebral microdialysis. 
Brains were processed for histopathology and (immuno)-histochemistry. 
Results Ten days after TBI, (R)-[11C]PK11195 binding was significantly 
increased in TBI rats compared with both baseline values and sham controls 
(p < 0.05). ECF glutamate values were increased immediately after TBI (27.6 
± 14.0 μmol·L-1) as compared with the sham procedure (6.4 ± 3.6 μmol·L-1). 
Significant differences were found between TBI and sham for ED-1, OX-6, 
GFAP, Perl's, and Fluoro-Jade B. 
Conclusions Increased cerebral uptake of (R)-[11C]PK11195 ten days after 
TBI points to prolonged and ongoing activation of microglia. This activation 
followed a significant acute posttraumatic increase in ECF glutamate levels. 
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Background 
Microglia are immunocompetent brain cells, expressing a variety of cytokine, 
chemokine, and neurotransmitter receptors, including receptors for 
glutamate, the principle excitatory amino acid (EAA) in the central nervous 
system (CNS), when activated (85). In the neuroinflammatory cascade that 
follows traumatic brain injury (TBI), activated microglia may play a crucial role 
in the aetiology and progression of excito-neurotoxic brain lesions. Excito-
neurotoxicity after TBI mainly results from excessive glutamate release with 
subsequent excessive influx of Ca2+, primarily mediated by N-methyl D-
aspartate (NMDA) glutamate receptors (86). Glutamate release induces 
excitotoxicity and contributes to the pathophysiology of numerous 
neurological diseases including ischemia, inflammation, epilepsy, and 
neurodegenerative diseases (87, 88). In TBI, glutamate is released in large 
quantities into the extracellular fluid (ECF) by neurons and glial cells. 
However, in the posttraumatic neuroinflammatory cascade the relation 
between initial glutamate release and time course of microglia activation is 
not yet clear. 
In vivo, activated microglia can be quantified using (R)-[11C]PK11195 
(1-[2-chlorophenyl]-N-methyl-N-[1-methyl-propyl]-3-isoquinoline 
carboxamide) and positron emission tomography (PET) (89, 90). In CNS 
diseases, transition of microglia from a normal resting state into a 
pathologically activated state has been associated with a marked increase in 
expression of the 18 kDa translocator protein (TSPO), previously known as 
the peripheral-type benzodiazepine receptor (91, 92). (R)-[11C]PK11195 is a 
highly selective ligand for TSPO, which can be used to monitor distribution 
and time course of microglia activation following TBI (90). 
The purpose of the present study was to investigate the feasibility of 
determining microglia activation over time following TBI, to determine such 
activation, and to relate these findings to glutamate release. To this end, in 
vivo cerebral microdialysis after TBI or sham was combined with sequential 
(R)-[11C]PK11195 brain PET scans and autopsy. 
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Methods 
Controlled cortical impact injury 
Wistar rats (male, body weight around 300 g, Harlan, The Netherlands) were 
either subjected to focal TBI (n = 6) or a sham procedure (n = 6). Anesthetic 
procedures and surgical preparation for controlled cortical injury (CCI) have 
been described previously (90). In short, rats were anaesthetized in a 
ventilated anesthesia chamber. After endotracheal intubation with a 16-
gauge Teflon catheter, rats were mechanically ventilated at a respiratory rate 
of 80 breaths per minute and remained under full anesthesia during the 
whole experiment (Isofluran 1-2%, oxygen 0.45 volume %). The iliac artery 
was cannulated with a 14G polymer catheter (length 25 mm) and connected 
to a pressure transducer to monitor blood pressure and obtain blood gases. 
Vital signs were monitored continuously and level of anesthesia was 
evaluated by monitoring the pinch reflex. Body temperature of the animals 
was kept within normal range (37 -38 °C) using cooling and heating pads. 
Animals were placed in a stereotactic frame, and a craniotomy was 
performed over the right parietal cortex between lambda and bregma and 
approximately 2.0 mm lateral to the central suture. A rounded impactor tip 
with a diameter of 7.0 mm was adjusted to produce an impact at the center of 
the exposed brain with an impact velocity of 5.0 m/s, duration of 130 ms, and 
an impact depth of 3.0 mm. Sham-operated rats underwent identical surgical 
procedures, except for the CCI. 
 
(R)-[11C]PK11195 PET 
(R)-[11C]PK11195 was synthesized according to the method described by 
Shah et al. (93). This procedure resulted in a good medical practice 
compliant, pyrogen-free, sterile batch of (R)-[11C]PK11195 with radiochemical 
purity of > 98% and mean specific activity of 100 ± 36 GBq·μmol-1. Rats were 
anaesthetized with Isofluran 5% in a ventilated anesthesia chamber, before 
breathing through a ventilation mask (Isofluran 1-2%, oxygen 0.45 volume %) 
during scanning. (R)-[11C]PK11195 was administered via a jugular vein 
cannula. In all rats (R)-[11C]PK11195 brain scans were performed 24 hours 
before intervention (baseline), and at one and ten days after TBI. 
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PET studies were performed using a single lutetium oxy-orthosilicate (LSO) 
crystal layer High Resolution Research Tomograph (HRRT, CTI/Siemens, 
Knoxville, TN, USA). The spatial resolution of this scanner is approximately 
2.5 mm in all directions, and the absolute point-source sensitivity is as high 
as 7%. Performance characteristics of this scanner have been reported 
previously (94). The combination of high spatial resolution and high 
sensitivity makes the HRRT an ideal PET scanner for dynamic studies in 
small laboratory animals (95, 96). 
First, a transmission scan was acquired using a 740 MBq 137Cs point 
source to correct for photon attenuation. Subsequently, following injection of 
(R)-[11C]PK11195, a dynamic emission scan with a total duration of 90 
minutes was acquired. All data were acquired in 64-bits list mode. After 
acquisition, list mode data were converted into 16 sinograms with frame 
durations increasing from 15 up to 300 s and reconstructed using a three-
dimensional ordered set expectation maximization (OSEM 3-D) algorithm 
with a matrix size of 256 × 256 × 207, resulting in a cubic voxel size of 1.21 × 
1.21 × 1.21 mm3. Administered (R)-[11C]PK11195 activity (15.8 ± 3.4 
MBq/rat) and mass (0.15 ± 0.03 nmol/rat) was not significantly different 
between TBI and control rats. 
 
Microdialysis 
PET and glutamate measurements were conducted in the same groups of 
animals. Immediately after CCI or sham procedure, in all rats a 2 mm-length 
microdialysis probe (CMA/12 14/02 PES CMA/Microdialysis, AB Solna, 
Sweden) with an outer diameter of 0.5 mm and a molecular weight cut-off of 
100 kDa, was placed stereotactically at a depth of 3 mm into the surrounding 
zone of the lesion or normal brain parenchyma (controls) according to the 
following coordinates: -1.5 mm from bregma, 3.0 mm lateral from midsagittal 
line. The inlet (12 cm) and outlet (7 cm) tubings from the microdialysis probe 
were connected to a syringe cannula and a microfraction collector, 
respectively. Exactly 5 minutes after CCI or sham, perfusion of the semi-
permeable system with artificial cerebrospinal fluid was started at a flow rate 
of 1.0 μl/min (Figure 1). Five sequential dialysate samples, at intervals of 60 
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minutes were collected and analyzed for glutamate using a CMA 600 
analyzer (CMA/Microdialysis, Solna, Sweden). 
 
 
Figure 1. Microdialysis catheter inserted into the brain parenchyma of an anaesthetized rat 
 
Animals remained in the stereotactic frame throughout the experiment. 
Vital signs were monitored continuously and the level of anesthesia was 
evaluated by monitoring the pinch reflex every 15 minutes. Body 
temperatures of the animals were kept within normal range (37 -38 °C) using 
cooling and heating pads. At the end of the experiment, the microdialysis 
probe was removed, the scalp incision closed and the rat removed from the 
stereotactic frame. After discontinuation of anesthesia, rats were extubated 
when breathing spontaneously and monitored until full recovery. 
Approval of the institutional animal ethics committee was obtained and 
all experiments were carried out in accordance with both the Dutch Law on 
Animal Experimentation and guidelines of the institutional committee on 
animal experimentation. 
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Brain tissue preparation 
Ten days after the experiment, the entire brain was removed promptly from 
the skull after decapitation. All brains were fixed in 4% buffered formalin, 
processed and embedded in paraffin according to routine procedures. Fixed 
axial tissue sections of 8.0 μm were mounted on coated slides and dried 
overnight at 37°C. Based on routine haematoxylin and eosin (HE) staining of 
all sections throughout the brain, selected slices of the lesion or sham region 
with an extra margin of 2.0 mm around this area were selected for 
(immuno)histochemical analysis. 
 
(Immuno)histochemistry 
Brain sections were immunohistochemically processed using appropriate 
primary antibodies: ED1 (1:100; mouse anti-rat lysosomal enzyme; Hycult 
Biotechnology, Uden, The Netherlands), GFAP (anti Ga5 1:200, Bioconnect, 
Huissen. The Netherlands), or OX-6 (1:200; mouse anti-rat MHC class II; 
AbD Serotec, Oxford, UK). After ED1 and GFAP staining, the Envision kit 
detection method (DAKO, Glostrup, DK) was used. For antibody OX-6, the 
Streptavidin-Biotin-horseradish peroxidase complex detection method was 
used (1:500, DAKO, Glostrup, DK). Negative controls were included by 
replacement of the primary antibodies with 1% bovine serum 
albumin/phosphate-buffered saline. Finally, visualization was performed 
using 0.02% 3.3'-diaminobenzidine tetrahydrochloride. Subsequently, 
sections were counterstained with haematoxylin, dehydrated and mounted. 
For histomorphological analysis of injury and inflammatory cells, 
routine HE staining was performed. Additionally, a routine Perl's iron staining 
was applied to identify the location of posttraumatic haemorrhages. An 
anionic fluorochrome, Fluoro-Jade B, was used as a marker for neuronal 
injury, delineating both degenerating neuronal cell bodies and its processes 
(97, 98). Briefly, after deparaffination and dehydration, sections were rinsed 
in distilled H2O and incubated at room temperature for 25 min in 0.06% 
potassium permanganate to ensure background suppression. After washing 
in distilled H2O, sections were incubated for another 30 min in a freshly 
prepared 0.001% Fluoro-Jade B solution. Finally, sections were washed 
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thoroughly in distilled H2O, dried for one hour at 37 °C, dipped in xylene and 
mounted. 
A pathologist (AJR) and two investigators (JCFD; CFMM) scored the 
ED-1, OX-6, Perl's and Fluoro-Jade B results. Scoring was divided into no, 
moderate and strong positivity. In addition, the size of positive areas was 
measured for ED-1 and OX-6. GFAP staining was assessed for increased 
density of GFAP-positive astrocytes at the ipsilateral compared to the 
contralateral side. 
 
Image analysis 
Time activity curves (TACs) of (R)-[11C]PK11195, reflecting delivery of the 
tracer to the brain and binding of the tracer to TSPO (right and left 
hemispheres), were derived for predefined volume of interest (VOI), drawn 
and copied from a standardized rat brain MR imaging, corrected for injected 
dose and animal weight, using the software package AMIDE (Amide 0.9.1 
http://amide.sourceforge.net). For every rat the injected dose was derived 
from a VOI encompassing the total image. The TAC for this VOI showed a 
maximum value in the initial frames, after which a decrease was observed 
due to accumulation into the bladder. The shape of various total image TACs 
was similar, allowing a good estimate of the injected dose from the maximum 
value of these curves. 
 
Statistical Analysis 
Statistical testing of areas under the curve between baseline TACs and TACs 
after TBI or sham were performed using a one tailed Student's t-test, testing 
the a-priori hypothesis that (R)-[11C]PK11195 will be increased after TBI. 
Microdialysis data are expressed as mean ± standard deviation. Statistical 
significance of differences in ECF glutamate between TBI rats and controls at 
all-time points was assessed using a one-tailed Student's t-test. 
Relationships between sham and TBI for all staining’s were calculated using 
Spearman's correlation statistics. Because of non-normal distribution and 
differences in homogeneity of variances in protein expression levels (OX-6, 
ED-1, Perl's and Fluoro-Jade B) and lesion size (OX-6, ED-1 and Perl's), as 
assessed by the Kolmogorov-Smirnov test of normality and the Levenes test, 
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statistical evaluation was performed using the non-parametric Mann-Whitney 
U test. P-values < 0.05 were considered statistically significant (SPSS 
version 15.0.1, SPSS Inc., Chicago, IL, USA). 
 
Results 
(R)-[11C]PK11195 PET 
In total, 28 PET scans were performed and 21 (R)-[11C]PK11195 scans (9 
baseline, 8 at day one (4 CCI, 4 sham), 4 at day 10 (2 CCI, 2 sham) were 
available for further analysis. Two rats died after the baseline scan, two rats 
died shortly after CCI and sham procedure due to cardiac arrest, and another 
four rats died before day ten. Representative examples of summed PET 
images of baseline, one and ten days after TBI or sham procedure are shown 
in Figure 2. One day after surgery, no statistically significant differences in 
(R)-[11C]PK11195 brain uptake were found between TBI and control rats, nor 
compared to baseline values. Ten days after TBI, however, an increase in 
cerebral uptake (SUV) of (R)-[11C]PK11195 was statistically significant in TBI 
rats (0.79 ± 0.07) compared with both corresponding baseline values (0.56 ± 
0.05, p = 0.006) and sham-operated animals (0.70 ± 0.06, p = 0.026) (Figure 
3). 
 
In vivo microdialysis 
Accurate microdialysis samples were obtained for six rats, three TBI and 
three sham (controls). In two rats, sampling failed because of leakage of the 
microdialysis probe. ECF glutamate values one hour after TBI were 
significantly higher than corresponding values in sham rats (27.6 ± 10.6 
μmol·L-1 and 6.4 ± 3.6 μmol·L-1, respectively; p < 0.05). Moreover, at all time 
points mean glutamate levels in TBI rats were higher than in sham controls 
(Figure 4). 
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Figure 2. Representative examples of summed PET images showing uptake of 
(R)-[11C]PK11195 in rat brain at baseline, one and ten days after TBI or sham 
 
 
 
 
 
Figure 3. Mean SUV of the image-derived injection dose (IDID) with error bars over time for 
baseline (--), sham (О) and TBI ( ) animals at 10 days 
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Figure 4. Dialysate glutamate concentrations as a function of time following CCI (♦ n=3) and 
sham (о n=3) (* p<0.05). Vertical lines represent SD. The arrow indicates baseline ECF 
glutamate release (sham) 
 
 
Immunohistochemistry 
Representative examples of brain tissue stained for ED-1, OX-6, GFAP, 
Perl's, and Fluoro-Jade B are shown in Figure 5. Morphology of ED-1-
positive cells clearly indicates highly activated microglia and/or macrophages. 
ED-1-positive cells were present in both TBI and sham-operated rats, but the 
size of the area of positive ED-1 staining was larger in the ipsilateral 
hemisphere of TBI rats, compared to both contralateral hemisphere and 
sham-operated rats (Figure 5 A+B). OX-6 staining was present 
predominantly in the ipsilateral hemisphere of TBI rats. It was minimal in the 
contralateral hemisphere and both hemispheres of sham-operated rats. OX-
6-positive cells were morphologically identified as activated microglia. The 
size of stained areas markedly differed between injured and non-injured brain 
tissue (Figure 5 C+D). GFAP expression in the injured hemisphere was 
increased compared with that in the contralateral hemisphere. In sham-
operated rats, the density of astrocytes was homogeneous over the entire 
brain (Figure 5 E+F). Perl's staining, indicative of haemorrhages, was clearly 
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increased in size and intensity in the injured hemisphere of TBI rats (Figure 5 
G+H). In TBI rats, Fluoro Jade B positivity was exclusively seen in the 
ipsilateral hemisphere of TBI rats (r = 0.83, p < 0.02). No Fluoro Jade B 
staining, indicating degenerating neurons was found in the contralateral 
hemisphere nor in sham brain tissue (Figure 5 I+J). 
 
 
 
Figure 5. Representative images of (immuno)histochemical staining of brain tissue (TBI and 
control) with ED-1, OX-6, GFAP, Perl's, and Fluoro-Jade B ten days after the microdialysis 
experiment 
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Discussion 
This study demonstrates the technical feasibility of TSPO imaging in 
experimental TBI. Correlations over time were investigated between 
posttraumatic microglia activation, determined by sequential (R)-
[11C]PK11195 scans, ECF glutamate release, measured with in vivo cerebral 
microdialysis, and (immuno)-histopathology in a rat model of TBI. An 
increase was found in (R)-[11C]PK11195 cerebral uptake ten days after TBI. 
Glutamate concentrations were increased one hour after TBI compared to 
those after sham procedure. 
To acquire pharmacologically and physiologically accurate ligand-
receptor binding data in small animals using HRRT, a high specific activity is 
required to maintain a low degree of receptor occupancy (99). The injected 
mass (0.15 ± 0.03 nmol/rat) in our study did not exceed the limits of site 
occupancy and is considered to be a tracer dosage. The significant increase 
in (R)-[11C]PK11195 uptake after TBI is in line with results of Toyama et al. 
(100), who found increased (R)-[11C]PK11195 binding in the injured site three 
days after an ethanol brain injury. Ito et al. (101) found significant differences 
in distribution volumes as well as an increased expression of inflammatory 
cytokines between injured and controls rats in specific brain areas four days 
after injury. Recently, Yu et al. (102) found a more-than-3-fold increase in 
[18F]fluoroethyl-DAA1106 uptake in traumatized brain tissue compared to 
controls, peaking one week after lateral fluid percussion brain injury. A 
relatively rapid accumulation of phagocytic microglia and macrophages at the 
necrotic core was reported, followed by increased TSPO expression. 
Although ECF glutamate was not measured, those findings are in line with 
the present results. 
Peak ECF glutamate concentrations were found in the first hour of the 
microdialysis experiment. In TBI rats, this peak concentration was 
significantly higher than in controls. Over subsequent hours, glutamate 
concentrations gradually declined in both groups, but remained higher in TBI 
rats than in sham rats. When data from cerebral microdialysis experiments 
are analysed, the component resulting from the surgical procedure itself has 
to be taken into account. By penetrating brain parenchyma, the microdialysis 
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catheter could give rise to a focal brain injury (84). Haemostatic and local 
environmental disturbances caused by this penetration might result in 
temporary alterations in glutamate concentrations in ECF. Woodroofe et al. 
(84) showed that, without additional trauma, microdialysis catheters gave rise 
to a local immune response in brain parenchyma two days after implantation. 
Pathological excessive glutamate release, exceeding excitotoxic thresholds, 
results in activation of postsynaptic ionotropic and metabotropic receptors 
(103). Activation of non-NMDA glutamate receptors generates an influx of 
monovalent cations (Na+ and K+) followed by a passive influx of water, 
inducing cytotoxic edema (104). Activation of NMDA glutamate receptors 
elicit an excessive influx of calcium, stimulating activation of phospholipases 
and generation of oxygen-derived free radicals (86). Taken together, this 
detrimental state of excitotoxicity results in apoptosis of resident cells of the 
brain (105, 106). Consequently, NMDA antagonists may be beneficial in 
preventing progressive brain injury after trauma (107). Indeed, efficacy of 
NMDA antagonists has been demonstrated in several preclinical brain injury 
studies. For instance, NMDA antagonists may be beneficial in preventing 
secondary neuronal damage by ischemia, neurological motor dysfunction, 
impairment in spatial memory and focal brain edema at the site of injury. 
Furthermore, they may affect synaptic plasticity (108-110). In addition, in situ 
administration of kynurenic acid, an EAA antagonist and specific NMDA 
receptor blocker, attenuates rapid microglial and astroglial reactions in rat 
hippocampus following TBI (111). Results of the present study underline that 
increased ECF glutamate concentrations in the acute posttraumatic phase 
precede increased microglial activation in traumatized brain tissue (112). 
Future studies should address whether there is a beneficial effect of EAA 
antagonists on late-phase microglia activation. 
Microglial activation and brain injury were assessed by 
immunohistochemical and Fluoro Jade B staining. From a morphological 
point of view, ED-1-positive cells are highly activated microglia and/or 
macrophages. The exclusive site where ED-1-positive cells were present was 
at the ipsilateral hemisphere of TBI rats. This is in accordance with a study by 
Lemstra et al. (113), who showed that CD68 is a lysosomal membrane 
marker and predominantly stains microglia in a highly active, phagocytic 
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state. OX-6 is another suitable marker of activated microglia, and OX-6 
staining demonstrated a clear difference between sham and TBI rats. The 
present results indicate that both density and area of OX-6-positive cells are 
higher at the site of injury. These findings indicate that activated microglia 
have migrated to the site of injury ten days after TBI which is in accordance 
with studies by Cho et al. (114). In TBI, Fluoro-Jade B is a very effective 
marker for locating degenerating neurons (97). In the present study, Fluoro-
Jade B-positive cells were only seen in the injured hemisphere. These 
findings, together with neuronal tissue damage and microglia activation at the 
site of the injury confirm increased (R)-[11C]PK11195 binding in the injured 
hemisphere in TBI rats, ten days after CCI. 
 
Conclusions 
Significantly increased cerebral uptake of (R)-[11C]PK11195 ten days after 
TBI points to prolonged and ongoing activation of microglia. This increased 
posttraumatic microglia activation follows an acute posttraumatic ECF 
glutamate release. 
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Abstract 
 
Background (R)-[11C]PK11195 is a tracer for activated microglia. The 
purpose of this study was to assess the validity of the simplified reference 
tissue model (SRTM) for analyzing (R)-[11C]PK11195 studies in traumatic 
brain injury (TBI), where blood–brain barrier disruptions are likely. 
Methods Dynamic (R)-[11C]PK11195 scans were acquired at 3 time points 
after TBI. Plasma input (PI)–derived binding potential (BPNDPI), volume of 
distribution (VT) and K1/k2, and SRTM–derived binding potential (BPNDSRTM) 
were obtained. Simulations were performed to assess the effect of varying 
K1/k2. 
Results Early after TBI, an increase in VT, but not in BPNDPI, was found. 
Early K1/k2 correlated with VT and BPNDSRTM but not with BPNDPI. One and 6 
months after TBI, BPNDSRTM correlated with BPNDPI. 
Conclusions Early after TBI, (R)-[11C]PK11195 studies should be analyzed 
using PI models.  
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Background 
Microglial activation can be measured using (R)-[11C]PK11195 and PET. This 
methodology has been used in the study of various neurodegenerative and 
neuroinflammatory diseases (115-120). Although the role of activated 
microglia after traumatic brain injury (TBI) is currently unknown, they may 
play a crucial role in this neuroinflammatory response after TBI and, as such, 
may be an important target for intervention after TBI. In vivo assessment of 
activated microglia after TBI is essential for developing such a strategy. 
In most studies, (R)-[11C]PK11195 binding has been quantified using 
reference tissue approaches (121-124). Assessment of (R)-[11C]PK11195 
binding after TBI, however, should take into account the added complexity of 
the fact that blood–brain barrier (BBB) disruptions are likely to be present. 
The purpose of this study was to assess the validity of reference tissue 
methods for quantifying (R)-[11C]PK11195 binding in TBI patients.  
 
Methods 
Subjects 
Ten TBI patients (mean age, 37.0 ± 17.2 y; range, 18–63 y; 6 men and 4 
women) and 7 healthy control subjects (mean age, 31.2 ± 15.5 y; range, 18–
59 y; 4 men and 3 women) were studied. Informed consent was obtained 
from all subjects or their next of kin. The clinical research protocol had been 
approved by the Medical Ethical Review Committee of the VU University 
Medical Center.  
 
Design 
All TBI patients were scheduled for the first (R)-[11C]PK11195 positron 
emission tomography (PET) scan 7–10 days after trauma. Follow-up PET 
scans were performed at 1 and 6 months after TBI. At least 24 hours before 
scanning, patients were deprived of nonsteroidal antiinflammatory drugs and 
benzodiazepines. All subjects underwent structural T1-weighted magnetic 
resonance (MR) imaging at the time of the PET scan. In TBI patients, a 
second MR scan was performed 6 months after TBI. All healthy subjects had 
normal screening results and normal MR findings. 
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(R)-[11C]PK11195 scans  
PET was performed using an ECAT EXACT HR+ scanner, equipped with a 
neuro insert. All subjects received an indwelling radial artery cannula for 
arterial blood sampling. After a 10-min 2-dimensional transmission scan, a 3-
dimensional dynamic (R)-[11C]PK11195 scan was obtained, consisting of 23 
frames and a total acquisition time of 62.5 min. A bolus of 398 ± 75 MBq of 
(R)-[11C]PK11195 was injected intravenously using an infusion pump. The 
administered activity of (R)-[11C]PK11195 was not significantly different 
between patients (395 ± 77 MBq; 46 ± 19 GBq·μmol−1) and healthy controls 
(438 ± 37 MBq; 75 ± 30 GBq·μmol−1). Arterial blood was withdrawn 
continuously at a rate of 5 mL·min−1 for the first 10 min and 2.5 mL·min−1 
thereafter. In addition, discrete blood samples were taken at set times (125). 
All PET scans were reconstructed using a Fourier rebinning algorithm plus a 
2-dimensional filtered backprojection algorithm with a Hanning filter set at a 
cutoff of 0.5 times the Nyquist frequency, resulting in an image resolution of 
about 7 mm in full width at half maximum (126). All data were corrected for 
decay, dead time, randoms, scatter, and tissue attenuation. A zoom factor of 
2 and an image matrix of 256 × 256 × 63 were used, resulting in a voxel size 
of 1.2 × 1.2 × 2.4 mm. 
 
Volume of interest definition 
MR and PET scans were coregistered (127, 128). Bilateral 3-dimensional 
volumes of interest (VOI) for frontal, parietal, occipital, temporal cortex 
cerebellum, thalamus, hippocampus, cingulate gyrus, striatum, corpus 
callosum, midbrain, pons, and medulla oblongata were outlined manually on 
the coregistered MR scan. In addition, areas of traumatic intracerebral 
contusion and the surrounding penumbra zones were defined. A global VOI 
was constructed, comprising the volume-weighted values of these regions. 
VOIs were projected onto the corresponding dynamic PET scans (all frames), 
generating regional time-activity curves (TAC). 
 
Kinetic and parametric Analysis 
Metabolite-corrected plasma input (PI) functions were generated as 
described previously and were used for a 2-tissue-compartment model. In 
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addition, uncorrected whole blood was used as a second input function for 
estimating blood volume fraction (129). With this model, tissue time–activity 
curves for all VOIs were analyzed, providing volume of distribution (VT), PI-
derived binding potential (BPNDPI), and K1/k2. Simplified reference tissue 
model (SRTM)–derived binding potential (BPNDSRTM) was obtained using 
SRTM, with total cerebellum as the reference tissue. 
 
Simulations 
To investigate the impact of changes in K1/k2 on the accuracy of all analyses, 
we performed simulation studies. For all simulations, the reference and target 
regions were simulated using a 2-tissue-compartment model. Nonspecific 
binding in reference and target regions was assumed to be the same and 
was set to a binding potential of 1.5 using a k5 of 0.06 min−1 and a k6 of 0.04 
min−1. Although, in reality, nonspecific binding may vary between regions, the 
purpose of the present simulations was only to assess the effect of changes 
in K1/k2. For the reference region, a K1 of 0.055 mL·cm−3·min−1 and a k2 of 
0.15 min−1 (K1/k2 = 0.367) were used, whereas for the target regions the 
K1/k2 ratio was varied either by changing K1 and keeping k2 constant or by 
changing k2 and keeping K1 constant. In this way, the K1/k2 ratio of the target 
region was varied between 0.2 and 0.6 - that is, with lower and higher K1/k2 
ratios than that of the reference region. Blood volume was set to 0.05 for both 
reference and target regions. Target region TACs were then analyzed using 
both a 2-tissue-compartment PI model and SRTM. Bias in observed binding 
potentials was evaluated as a function of simulated K1/k2 of the target region. 
 
Results 
Subjects 
In TBI patients, (R)-[11C]PK11195 scans were obtained at 10 ± 4 (n = 9), 42 ± 
10 (n = 8), and 185 ± 17 (n = 9) days after TBI, with reliable PI data for 5, 5, 
and 8 scans, respectively. SRTM data were available for 8 TBI patients and 
all controls. 
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Figure 1. K1/k2, VT, and BPNDPI in TBI patients at 7–10 d (♦) 1 mo (▪) and 6 mo (▴) after TBI 
and in control subjects (○) 
 
[11C]PK11195 PET studies  
K1/k2, VT, and BPNDPI values for the global VOI are shown in Figure 1. Seven 
to 10 days after TBI, K1/k2 was decreased, compared with 1 month (p=0.005) 
and 6 months (p=0.0002) after TBI and compared with healthy controls 
(p=0.015). In addition, the early scans showed a VT decrease that was 
proportional to the decrease in K1/k2. One and 6 months after TBI, global 
K1/k2 normalized to the values seen in the healthy controls (p=0.33 and 
p=0.27, respectively). Similar variations in VT over time were seen, whereas 
binding potentials appeared to be more constant on average.  
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Figure 2. BPNDSRTM (A) as function of BPNDPI for thalamus and trauma/penumbra at 1 and 6 
mo after TBI; BPNDSRTM (B) and BPNDPI f (C) as function of K1/k2; and BPNDSRTM (D) as 
function of K1/k2 normalized to reference (cerebellum) K1/k2. Circled data points represent 
low BPNDSRTM (A) because of low K1/k2 ratio (B). 
 
Because K1/k2 abnormalities normalized at 1 and 6 months, BPNDSRTM 
could be a valid approach for estimating BPND at these time points. This 
possibility was further assessed through a comparison of BPNDSRTM with 
corresponding BPNDPI values. In Figure 2A, combined results for thalamus 
and trauma/penumbra VOI (regions with the highest signal) are provided and 
show a clear proportionality between BPNDSRTM and BPNDPI. The observed 
offset around a BPNDPI of 2.0 corresponds to the value seen in healthy 
controls (89). In Figures 2B and 2C, BPNDPI and BPNDSRTM, respectively, are 
shown as functions of K1/k2 obtained from plasma input analysis. No 
significant correlations (R2 < 0.2) were observed. The 3 outliers encircled in 
Figure 2A correspond to those encircled in Figure 2B, that is, to the lowest 
K1/k2 values. Finally, Figure 2D shows the relationship between BPNDSRTM 
and K1/k2normalized to that of the reference VOI (total cerebellum). Again, 
no significant correlations were observed (R2 < 0.2). 
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Figure 3. BPNDSRTM (A) as function of BPNDPI; BPNDSRTM (□) and BPNDPI (♦) (B) as function of 
K1/k2; and BPNDSRTM (C) as function of K1/k2 normalized to reference (cerebellum) K1/k2. 
 
The results for early (R)-[11C]PK11195 scans in TBI patients are 
shown in Figure 3. In Figure 3A, BPNDSRTM for various trauma or penumbra 
regions is given as a function of the corresponding BPNDPI. In contrast to the 
late scans (Figure 2A), no clear correlation between BPNDSRTM and BPNDPI 
was observed. In Figure 3B, both BPND measures are given as a function of 
K1/k2, and in Figure 3C, BPNDSRTM is shown as a function of K1/k2 normalized 
to that of the reference region. In the latter case, a high correlation (R2 = 
0.85) was observed. 
 
Simulations 
The results of the simulation studies for both plasma and reference tissue 
input models are shown in Figure 4. Changing the K1/k2 ratio of the target 
region did not affect BPNDPI, indicating that changes in K1 or k2, and thus in 
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K1/k2, are considered correctly. On the other hand, a change in the K1/k2 
ratio of the target region relative to that of the reference VOI (indicated by the 
arrow) resulted in a corresponding bias in BPND estimates.  
 
 
Figure 4. BPNDSRTM (□) and BPNDPI (♦) as function of K1/k2, with K1/k2 of reference tissue 
fixed to value indicated by arrow. Horizontal lines represent BPNDSRTM and BPNDPI values for 
case in which K1/k2 is same as that of reference tissue. 
 
Discussion 
This study showed that BPNDSRTM overestimated specific (R)-[11C]PK11195 
binding in scans obtained 7-10 days after TBI, especially in contusion areas. 
As such, an increase in BPNDSRTM early after TBI could be a false-positive 
finding that is due to BBB disruptions rather than microglial activation. 
Analysis using a PI model showed a global decrease in K1/k2 values in (R)-
[11C]PK11195 scans obtained 7-10 days after TBI, compared with K1/k2 
values in healthy volunteers. Moreover, (R)-[11C]PK11195 scans obtained 7-
10 days after TBI showed more variability in K1/k2 than was seen in healthy 
controls. This increased variability of K1/k2 across the brain most likely 
reflects disruptions of the BBB, which would prohibit definition of an 
appropriate reference tissue. In contrast, the increase in BPND seen in 
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patients at 1 and 6 months after TBI is likely to reflect specific (R)-
[11C]PK11195 binding, as it is associated with an increase in k3/k4 without an 
increase in K1/k2. Because the variability of K1/k2 across the brain was also 
similar to that in healthy subjects, SRTM seems to be a valid method for 
assessing activated microglia at 1 and 6 months after TBI. Clearly, if early 
scans are involved, all longitudinal scans, even those beyond 1 month after 
TBI, should also be analyzed with a PI model. 
In line with many previous studies, total cerebellum was used as the 
reference tissue (115, 118, 120, 123). PI analysis revealed that cerebellar 
BPNDPI was 1.92 ± 0.23 and 1.50 ± 0.44 in early and late scans, respectively. 
In healthy controls, BPNDPI was 1.35 ± 0.29. These data indicate that 
activated microglia may indeed be present in cerebellum (P = 0.004) early (7-
10 days) after TBI, whereas the difference from healthy controls is no longer 
significant (p=0.23) for later (1-6 months after TBI) studies. In other words, 
use of SRTM early after TBI is affected not only by BBB abnormalities but 
also possibly by the presence of activated microglia in the reference tissue. 
Thus, for early TBI scans, a PI function is needed for which arterial sampling 
is required. A drawback of arterial sampling is its invasiveness. In addition, 
arterial sampling is more labor-intensive and cannot always be successfully 
completed, especially in TBI patients. 
Disruptions of the BBB are not unique to TBI. Indeed, BBB disruptions 
often are diagnosed in other disorders such as stroke, multiple sclerosis, 
hereditary cerebral hemorrhage with amyloidosis–Dutch type, cerebral 
amyloid angiopathy, and brain tumors. In addition, the results from the 
present study can be extrapolated to all cases of suspected BBB disruption. 
In those cases, reference tissue approaches, such as SRTM, cannot be used 
to assess specific binding.  
 
Conclusions 
In the acute or subacute phase after TBI, (R)-[11C]PK11195 studies should 
be analyzed using only PI models. At later stages, reference tissue models 
might also be valid for assessing activated microglia. 
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Abstract 
Background Our objective was to measure (R)-[11C]PK11195 binding as an 
indirect marker of neuronal damage after traumatic brain injury (TBI). 
Methods Dynamic  (R)-[11C]PK11195 positron emission tomography (PET) 
scans were acquired for 8 patients 6 months after TBI and for 7 age-matched 
healthy controls. (R)-[11C]PK11195 binding was assessed using the simplified 
reference tissue (SRTM) model. Because of widespread traumatic changes 
in TBI, an anatomic reference region could not be defined. Therefore, 
supervised cluster analysis (SVCA4) was used to generate an appropriate 
reference tissue input. 
Results Increased whole-brain binding of (R)-[11C]PK11195 was observed in 
TBI patients. Regional analysis indicated that increased (R)-[11C]PK11195 
binding was widespread over the brain. 
Conclusion Six months after TBI, there was a prolonged and widespread 
increase in (R)-[11C]PK11195 binding, which is indicative of diffuse neuronal 
damage.  
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Background 
Traumatic brain injury (TBI) is the leading cause of death and disability 
among young people under the age of 40 years. Frequently, survivors of TBI 
(and their relatives) have to deal with the devastating consequences of 
prolonged neurologic and cognitive impairments (130). Worldwide, an 
estimated 1.2 million people are killed in road crashes each year and as 
many as 50 million are injured. According to the World Health Organization 
(WHO), these figures will increase by about 65% over the next 20 years 
(131). From this point of view, TBI is a tremendous burden on society. 
In TBI, structural intracranial abnormalities such as hemorrhages and 
edema can be visualized by computed tomography (CT) and magnetic 
resonance (MR) imaging. Complementary to those, positron emission 
tomography (PET) techniques can be used to demonstrate and evaluate 
posttraumatic disturbances in, for example, brain metabolism or brain 
function. Already by the mid-1980s, PET studies on TBI patients had been 
performed, mainly with 18F-FDG. Langfitt et al. found extensive disturbances 
in glucose metabolism beyond structural abnormalities demonstrated by CT 
and MR (132). Their findings were in line with studies performed by Rao et al. 
(133). They found that the results from PET studies closely corresponded to 
the site and extent of cerebral dysfunction, determined by neurologic and 
behavioral examinations, whereas CT did not. Follow-up CT studies, 
however, demonstrated structural abnormalities consistent with the early PET 
findings, supporting the predictive value of 18F-FDG PET (133). More 
recently, diffuse cerebral hypometabolism has also been demonstrated in 
boxers with neurologic and cognitive disabilities as a consequence of chronic 
TBI and in war veterans with persistent post concussive symptoms (134, 
135). 
Today, research in the field of TBI is becoming increasingly focused 
on posttraumatic neuroinflammation. It has been suggested that microglial 
activation may play an important role in a variety of neuroinflammatory and 
neurodegenerative diseases (116, 136). Microglial activation is thought to be 
closely associated with neuronal damage. As such, activated microglia may 
also be involved after head trauma. In addition, microglia are capable of 
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synthesizing immune mediators, including cytokines, chemokines, and 
complement activation proteins, and of expressing specific receptors of these 
immune mediators (19). In this context, the putative role of activated 
microglia in TBI is that they serve as the major antigen-presenting cells in 
brain tissue, which are crucial in the highly complex neuroinflammatory 
cascade after brain injury. Microglial imaging in TBI patients can be of 
meaningful clinical and diagnostic value in terms of visualization and 
quantification of active disease processes, though the long-term effects of 
microglial activation in the posttraumatic neuropathologic sequelae after TBI, 
together with its implications for neurologic outcome, have not been 
elucidated yet. 
(R)-PK11195 (1-[2-chlorophenyl]-N-methyl-N-[1-methyl-propyl]-3-
isoquinoline carboxamide) is a selective ligand for activated microglia. When 
labeled with the positron emitter 11C, it can be used to quantify microglial 
activation in vivo using PET. This approach has already been used in the 
study of several neurodegenerative disorders (116, 117, 122). The main 
purpose of the present study was to quantify (R)-[11C]PK11195 binding in 
patients with moderate and severe TBI, six months after injury. 
 
Methods 
Subjects 
Eight patients (5 men and 3 women; age range, 18–63 y) with moderate 
(n=5) or severe (n=3) TBI (total Glasgow Coma Scale (GCS) on the day of 
trauma, 9-13 and ≤8, respectively) were studied (Table 1). In addition, 7 age- 
and sex-matched healthy controls (4 men and 3 women; age range, 18–59 y) 
were included after a standardized physical and mental health screening, 
including a normal brain MR result as judged by a neuroradiologist. Written 
informed consent was obtained from all patients or their next of kin and from 
all healthy controls. In accordance with the Declaration of Helsinki, the 
clinical research protocol had been approved by the Medical Ethics Review 
Committee of the VU University Medical Center, Amsterdam, The 
Netherlands. 
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Study design 
For all subjects, both (R)-[11C]PK11195 and MRI scans of the brain were 
acquired within the same week. In TBI patients, the procedure was 
performed 6 months after injury. None of the TBI patients or the healthy 
controls was on nonsteroidal antiinflammatory drugs or benzodiazepines.  
 
(R)-[11C]PK11195 PET scans  
(R)-[11C]PK11195 PET scans were acquired using an ECAT EXACT HR+ 
scanner (Siemens/CTI), equipped with a neurologic insert. (R)-[11C]PK11195 
was produced according to the method of Shah et al. (93). After a 10-min 
transmission scan in 2-dimensional acquisition mode, a 3-dimensional 
dynamic (R)-[11C]PK11195 scan was obtained, consisting of 23 frames of 
increasing length and a total acquisition time of 62.5 min. A bolus of (R)-
[11C]PK11195 was injected intravenously using a fully automated infusion 
pump. Administered (R)-[11C]PK11195 activity was not significantly different 
between patients (422 ± 49 MBq) and healthy controls (438 ± 37 MBq; P = 
0.67), nor was there a significant difference in specific activity between 
patients (48.1 ± 16.5 GBq/μmol) and healthy controls (75.1 ± 30.3 GBq/μmol; 
P = 0.065). Injected mass was 3.3 ± 0.9 μg for TBI patients and 1.5 ± 0.3 μg 
for healthy controls (P = 0.003). All PET scans were reconstructed using a 
Fourier rebinning algorithm plus 2-dimensional filtered backprojection, with a 
Hanning filter at a cutoff of 0.5 times the Nyquist frequency, resulting in an 
image resolution of approximately 7 mm in full width at half maximum (126). 
All data were corrected for decay, dead time, randoms, scatter, and tissue 
attenuation. A zoom factor of 2 and an image matrix size of 256 × 256 × 63 
were used, resulting in a voxel size of 1.2 × 1.2 × 2.4 mm.  
 
Kinetic and parametric analysis 
Parametric (R)-[11C]PK11195 nondisplaceable binding potential (BPND) 
images were generated using reference parametric mapping (137), a basis 
function implementation of the simplified reference tissue model (124). A 
modified supervised cluster analysis algorithm (SVCA4) was used to extract 
the reference tissue input curve (138). In a previous study, the use of a 
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simplified reference tissue model for analyzing (R)-[11C]PK11195 data 6 
months after TBI was validated (139). 
 
Volume of interest definition 
PET and MRI scans were coregistered using the software package MIRIT 
(127). Volumes of interest for cerebellum, frontal lobe, parietal lobe, temporal 
lobe, occipital lobe, ventromedial prefrontal cortex, hippocampus, cingulate 
gyrus, caudate nucleus, basal ganglia, midbrain, pons, and medulla, 
including posttraumatic intracranial lesions as determined by CT and MRI, 
were defined manually on the coregistered MRI scans using a dedicated 3-
dimensional software package (http://www.idoimaging.com/program/172). 
Regional values of BPND were obtained by projecting all volumes of interest 
onto the parametric (R)-[11C]PK11195 BPND images. Whole-brain BPND was 
defined as the volume-weighted average of these regional volume-of-interest 
values.  
 
Clinical Evaluation 
Six months after injury, the extended Glasgow Outcome Scale (GOS-E) was 
defined in all TBI patients (1 = dead, 2 = vegetative state, 3 = lower severe 
disability, 4 = upper severe disability, 5 = lower moderate disability, 6 = upper 
moderate disability, 7 = lower good recovery, and 8 = upper good recovery). 
Patient characteristics are shown in Table 1. 
 
Statistical analysis 
The Student t test was used to assess differences in brain BPND between TBI 
patients 6 months after head injury and age- and sex-matched healthy 
controls. Significance level was defined as P < 0.05. 
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Results 
 
Subjects 
Patient characteristics are shown in Table 1. The mean age of the eight 
consecutive TBI patients was 40.5 ± 17.0 year (range, 18–63 year). The 
mean initial GCS was 9 (range, 3–13). GOS-E at 6 months ranged from 4 to 
8.  
 
 
Table 1. Patient characteristics 
 
(R)-[11C]PK11195 PET  
Whole-brain analysis revealed a significantly (P = 0.02) increased (R)-
[11C]PK11195 BPND in TBI patients (BPND = 0.22 ± 0.08) 6 months after head 
injury, as compared with age-and sex-matched healthy controls (BPND = 0.12 
± 0.06) as illustrated in Figure 1. Increased (R)-[11C]PK11195 BPND was 
found not only in the affected brain regions but also in nontraumatic brain 
regions as determined by MR (Figure 2). On an individual basis, no clear 
correlation was found between the severity of head injury in terms of GCS or 
outcome (GOS-E) and whole brain (R)-[11C]PK11195 BPND. Maximum (R)-
[11C]PK11195 was found in the thalamus in 6 of 8 TBI patients. In 1 severe 
TBI patient (GCS 3) and 1 moderate TBI patient (GCS 13), the maximum (R)-
[11C]PK11195 BPND was found in the hippocampus and medulla, respectively 
(Table 1). Increased (R)-[11C]PK11195 was found in several brain areas of 
TBI patients: left and right frontal lobe, left and right thalamus, left parietal 
lobe, right temporal lobe, hippocampus and putamen, midbrain and pons 
(BPND = 0.36 ± 0.12, P < 0.01) (Table 2). The higher injected mass in 
patients cannot explain the higher BPND. If anything, it should have resulted 
in lower BPND values.  
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Table 2. (R)-[11C]PK11195 BPND for specific brain regions in TBI patients and healthy 
controls 
 
 
 
Figure 1. Scatterplot of whole brain (R)-[11C]PK11195 BPND in healthy controls and TBI 
patients 6 months after injury. Mean values are represented by horizontal lines 
 
 
 
 
Microglia activation after TBI 65 
 
 
 
Figure 2. Parametric (R)-[11C]PK11195 BPND images for healthy control (A), TBI patients 
with focal injury (B, D, and F), and TBI patients with diffuse injury (C and E). Images were 
generated using reference parametric mapping, with reference tissue input function 
generated by supervised cluster analysis. (A) Representative picture of healthy control. (B) 
Increased ipsilateral (R)-[11C]PK11195 BPND at site of hemicraniectomy. (C) Significant 
bilateral globally increased (R)-[11C]PK11195 BPND. (D) Increased pericontusional thalamic 
and cerebellar (R)-[11C]PK11195 BPND. (E) Increased thalamic (R)-[11C]PK11195 BPND at 
midbrain and occipital lobe. (F) Contrecoup increased (R)-[11C]PK11195 BPND in 
parietooccipital lobe 
 
 
Discussion 
To our knowledge, this was the first proof-of-concept study that showed a 
significant increase in both whole-brain and regional (R)-[11C]PK11195 BPND 
6 months after TBI, indicating prolonged and widespread microglial activation 
after head injury. 
The role of activated microglia after TBI is still poorly understood. In 
vitro studies, animal models, and in vivo clinical studies have demonstrated 
that activated microglia produce a myriad of inflammatory mediators (116, 
136, 140). Apart from being an important defense mechanism against 
invading pathogens, activated microglia may also be involved in the 
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pathogenesis of neuronal brain damage. In TBI, as a consequence of the 
initial insult, dying or damaged neurons activate resting microglia in brain 
tissue. Subsequently, these activated microglia produce not only 
neurotrophic but also neurotoxic factors, which may further damage 
surrounding neurons, resulting in ongoing bystander neurotoxicity (141). As 
clearly stated by Banati, injured brain is less static than commonly thought 
and shows subtle glial responses even in regions that appear 
macroanatomically stable. Glial activation is not solely a sign of tissue 
destruction but may also indicate disease-induced adaptation or plasticity 
(142). 
TBI can be seen as a global brain disease. Widespread 
pathophysiologic changes without any structural damage of affected regions, 
combined with the generally low signal-to-noise ratio of (R)-[11C]PK11195, 
preclude an anatomic definition of a reference region (e.g., cerebellum). In 
supervised cluster analysis, by using predefined kinetic classes, a gray 
matter reference tissue input without specific tracer binding (i.e., without 
activated microglia) is extracted (138). Using SVCA4, a specific 
implementation of supervised cluster analysis, it was possible to generate an 
appropriate and reliable reference tissue input and analyze the data with the 
validated reference tissue approach. 
From this series, increased and prolonged (R)-[11C]PK11195 binding 
was found in TBI patients, as compared with healthy controls (Figure 1). Not 
only in the ipsilateral but also in the contralateral hemisphere was increased 
(R)-[11C]PK11195 binding demonstrated, indicating more widespread 
neuronal damage (Figure 2). Clinical reading of MR scans showed far less 
affected regions in the brains of TBI patients, indicating that (R)-
[11C]PK11195 may be a sensitive marker for neuronal damage after TBI. 
Prolonged microglial activation in specific areas in the ipsi- and 
contralateral hemispheres stresses the importance of prevention and 
treatment of secondary injury in management of severe TBI patients. 
Therefore, (R)-[11C]PK11195 PET could become an attractive additional 
technique, which needs to be further evaluated, in detecting secondary injury 
after TBI. Currently, PET in TBI is of limited clinical applicability because of 
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the high costs, complex logistic and infrastructural setup, and time-
consuming analysis of limited clinical use. 
 
Conclusion  
From a scientific point of view, (R)-[11C]PK11195 PET has a high potential to 
become a sophisticated diagnostic molecular imaging technique that could 
contribute to the growing knowledge of secondary injury mechanisms in TBI. 
Further research is needed to elucidate whether and how the prolonged 
increase in (R)-[11C]PK11195 binding after TBI reflects ongoing and possibly 
preventable progressive neuronal damage. If this is the case, controlling 
microglial activation may lead to a better outcome after TBI. 
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Abstract 
Background To assess longitudinal changes in microglia activation in 
traumatic brain lesions and surrounding perilesional zones.  
Methods At three different time points, fully quantitative (R)-[11C]PK11195 
positron emission tomography (PET) scans with arterial sampling were 
performed in seven traumatic brain injury (TBI) patients. (R)-[11C]PK11195 
binding potential (BPND), K1/k2 and volume of distribution (VT) of traumatic 
brain lesions and surrounding perilesional zones were measured using a 
validated tracer kinetic model with metabolite-corrected plasma input 
function. Results were compared with normal values of seven age- and 
gender- matched healthy controls. 
Results A total of 11 traumatic brain lesions could be defined on magnetic 
resonance (MR) imaging scans. In the acute stage (7-10 days) in traumatic 
brain lesions and six months after TBI in perilesional zones, significantly 
higher (R)-[11C]PK11195 BPND values were found compared to healthy 
controls (p<0.01 and p=0.02, respectively). K1/k2 ratio values were 
significantly decreased in traumatic brain lesions, 7-10 days after TBI, 
compared to healthy controls (p=0.02). VT values were significantly increased 
in traumatic brain lesions at one month (p=0.04) after TBI and in the 
perilesional zones at one and six months after TBI compared to healthy 
controls (p=0.03 and p<0.01, respectively).  
Conclusions Increased (R)-[11C]PK11195 BPND in perilesional zones after 
TBI indicates microglia activation and/or macrophage influx in these regions. 
In traumatic brain lesions, the significant decrease in K1/k2 in early scans can 
be explained by disruption of the blood brain barrier (BBB). Prolonged 
increase in (R)-[11C]PK11195 binding in perilesional zones points to long-
term posttraumatic microglia activation, which may be a therapeutic target for 
future neuroprotective studies. 
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Background 
There is growing evidence that activated microglia and infiltrating immune 
cells play a crucial role in the complex neuroinflammatory cascades that 
ensue in response to common diseases of the central nervous system 
(CNS). When activated, microglia transform into cells that are 
indistinguishable from peripheral macrophages, secreting cytokines and 
acting as antigen-presenting cells (143). Translocator proteins (TSPO), 
previously referred to as peripheral benzodiazepine receptors, are highly 
expressed by activated microglia and can be visualized and quantified using 
(R)-[11C]PK11195 and positron emission tomography (PET) (23). 
In traumatic brain injury (TBI), blood brain barrier (BBB) disruptions 
lead to increased permeability resulting in leucocyte infiltration, microglia 
activation and inflammation (17). As a result of this extensive BBB 
breakdown, perilesional zones surrounding traumatic brain lesions are prone 
to massive additional neuronal brain damage. Recently, we reported on-
going increased cerebral uptake of (R)-[11C]PK11195, up to six months after 
injury, has been reported (144), suggesting diffuse neuronal damage. The 
purpose of the present study was to elucidate whether posttraumatic BBB 
disruptions in focal traumatic brain lesions and surrounding perilesional 
zones, as visualized by standard MR imaging, result in prolonged neuronal 
damage. 
 
Methods 
Subjects 
Seven consecutive TBI patients with moderate to severe TBI (Glasgow Coma 
Scale 9–13 and ≤8, respectively) and seven healthy, age- and gender- 
matched controls were included in the study. Written informed consent was 
obtained from all patients, or their legal representatives, as well as from all 
controls. The Clinical research protocol had been approved by the the 
Medical Ethical Review Committee of the VU University Medical Center, 
Amsterdam, The Netherlands. 
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Study design 
Patients were scheduled for the first (R)-[11C]PK11195 PET-scan 7-10 days 
after TBI. Follow-up scans were performed at one and six months after 
trauma. All subjects underwent structural T1-weighted MR scans of the brain 
at the time of the first PET scan. In TBI patients, a second MR scan was 
performed at the time of the third PET scan. All healthy subjects had normal 
screening results and normal MR findings. None of the TBI patients and 
healthy controls was on non-steroidal anti-inflammatory drugs or 
benzodiazepines. 
 
MR and (R)-[11C]PK11195 PET 
All subjects underwent structural T1-weighted MR scans of the brain using a 
Siemens 1T IMPACT scanner (Siemens Medical Solutions, Erlangen, 
Germany). PET scans were performed using an ECAT EXACT HR+ scanner 
(Siemens/CTI, Knoxville, TN, USA) (145). All subjects received an indwelling 
radial artery cannula for arterial sampling. After a 10 minutes’ transmission 
scan, an (R)-[11C]PK11195 scan was performed consisting of 23 frames with 
progressive increase in frame duration and a total acquisition time of 
62.5 minutes. A bolus of (R)-[11C]PK11195 was injected intravenously using 
a fully automatic infusion pump (Medrad Inc., Indianola, MS, USA). Arterial 
blood was monitored continuously using an online detection system (146) 
with a withdrawal rate of 5 mL/min during the first 10 minutes and 2.5 mL/min 
thereafter. In addition, at set times (2.5, 5, 10, 20, 30, 40, and 60 minutes 
postinjection), discrete manual arterial blood samples were taken. These 
were used for calibrating the (online) blood sampler, for measuring 
plasma/whole blood ratios, and for determining metabolite fractions (125), 
enabling the generation of a metabolite corrected arterial plasma input curve. 
 All PET scans were reconstructed using a FORE+2D filtered back 
projection algorithm with a Hanning filter at a cut off of 0.5 times the Nyquist 
frequency, resulting in an image resolution of ~7 mm full width at half 
maximum (126). All data were corrected for decay, dead time, randoms, 
scatter, and tissue attenuation. A zoom factor of 2 and an image matrix size 
of 256 × 256 × 63 were used, resulting in a voxel size of 1.2 × 1.2 × 2.4 mm3. 
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Volumes of interest definition 
PET and MR scans were co-registered using the software package MIRIT 
(127). Volumes of interest (VOI) of traumatic brain lesions, as defined by T1-
weighted hyperintense foci on axial T1-weighted MR images and a 
perilesional zone of one cm surrounding each traumatic brain lesion were 
defined. Next, well-defined 3D VOIs were obtained using a dedicated 
software package (http:www.bic.mni.mcgill.ca/software/Display); which 
enables display of 3D VOIs in coronal and sagittal views. Subsequently, both 
traumatic brain lesions and perilesional VOIs were projected onto the 
dynamic PET-scans to extract time activity curves (TAC). Next, TACs were 
analysed using a plasma input (PI) reversible two-tissue compartment model, 
including a parameter for the blood volume fraction (129), yielding BPND, 
K1/k2 and VT as primary outcome measures. 
 
Statistical analysis 
Continuous variables were tested with the Shapiro-Wilk test for normal 
distributions (values > 0.9 were considered normally distributed). Normally 
distributed variables were expressed as means with standard deviations (sd) 
and tested with the Student’s T test. Unequally distributed variables were 
expressed as medians with interquartile ranges (IQR 25%-75%) and tested 
with the Mann-Whitney U test. Values of p < 0.05 were considered 
statistically significant. Statistical analyses were performed using the 
Statistical Package for the Social Sciences (SPSS) 19.0 (IBM Business 
Analytics, New York, USA).  
 
Results 
Subjects 
Seven consecutive TBI patients (4 men; age range 18-63 year) with 
moderate (n=5) or severe (n=2) TBI and seven healthy, age- and gender- 
matched controls (4 men; age range 18-59 year) were included in the study. 
Eleven significant traumatic brain lesions in temporal (n=4), frontal (n=3), 
parietal (n=3), and occipital (n=1) lobes were identified (Table 1). 
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age (y) sex lesion GCS  
18 M ASDH 3 
18 M ASDH 3 
63 F EDH + contusion 9 
22 F DAI + contusions 9 
32 M DAI + contusions 10 
54 M DAI + contusions 13 
46 F contusions 13 
Table 1. Patient characteristics y=years; M=male; F=female; ASDH=acute subdural 
hematoma; EDH=extradural hematoma; DAI=diffuse axonal injury; GCS=Glasgow Coma 
Scale 
 
(R)-[11C]PK11195 PET-studies 
The dose of (R)-[11C]PK11195 administered was not significantly different 
between patients (422 ± 49 MBq) and healthy controls (438 ± 37 MBq; 
p=0.67), nor was the specific activity significantly different between patients 
(48 ± 16 GBq·µmol-1) and healthy controls (75 ± 30 GBq·µmol-1; p=0.06). 
Injected mass, however, was 3.3 ± 0.9 µg for TBI patients and 1.5 ± 0.3 µg 
for control subjects (p<0.01). 
Individual (R)-[11C]PK11195 BPND, K1/k2 and VT for traumatic brain 
lesions and perilesional zones at three different time points are shown in 
Figure 1, which also includes corresponding data for the healthy controls. In 
traumatic brain lesions, significantly increased (R)-[11C]PK11195 BPND 
values were seen in the acute stage (7-10 days) compared to healthy 
controls (p<0.01). In the perilesional zones, (R)-[11C]PK11195 BPND values 
were increased compared with healthy controls at six months (p=0.02). 
Typical examples of VT images at an early and late stage after TBI are 
shown in Figure 2. VT images were generated using PI Logan plot analysis, 
as previously described by Schuitemaker et al. (147). 
 
(R)-[11C]PK11195 in TBI 75 
 
 
Figure 1.  Graphs of BPND, K1/k2 and VT for traumatic brain lesions (A, C, E resp.) and 
perilesional zones (B, D, F resp.) at 7-10 days (♦), 1 (■) and 6 (▲) months after TBI 
compared to corresponding values in healthy controls (●) 
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Figure 2. Parametric volume of distribution (VT) images generated using plasma input Logan 
plots. Top and bottom rows illustrate images obtained at 7-10 days and 6 months after TBI, 
respectively, showing prolonged increased VT. 
 
In the acute stage (7-10 days) after TBI, significantly decreased K1/k2 
values were found in traumatic brain lesions compared to healthy controls 
(p=0.02). One month after TBI, VT values were significantly increased in 
traumatic brain lesions and in the perilesional zones compared to healthy 
controls (p=0.04 and p=0.03, respectively). Six months after TBI, VT values 
were significantly increased in the perilesional zones compared to healthy 
controls (p<0.01). 
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 traumatic VOIs   perilesional VOIs   controls 
 7-10 d 1 mo 6 mo 7-10 d 1 mo 6 mo   
BPND 3.53 ± 1.63* 2.27 ± 0.91 3.61 ± 2.55 2.14 ± 0.50 1.91 ± 0.37 2.91 ± 0.83* 1.74 ± 0.26 
K1/k2 0.17 ± 0.08* 0.35 ± 0.13 0.22 ± 0.09 0.21 ± 0.09 0.36 ± 0.06 0.30 ± 0.03 0.29 ± 0.07 
VT 0.72 ± 0.29 1.08 ± 0.23* 0.89 ± 0.15 0.66 ± 0.26 1.04 ± 0.14* 1.17 ± 0.25* 0.80 ± 0.17 
Table 2. Mean ± sd of BPND, K1/k2 and VT values for traumatic brain lesions and perilesional 
zones at 7-10 days, 1 and 6 months after TBI together with the corresponding values in 
healthy controls; * = statistically significant increase/decrease compared to healthy controls 
(p<0.05) 
 
Discussion 
Longitudinal changes in (R)-[11C]PK11195 BPND, K1/k2 and VT in both focal 
traumatic brain lesions and surrounding perilesional zones reflect early 
posttraumatic microglia activation and/or macrophage influx in traumatic 
brain lesions, together with disruption of BBB integrity and long-term on-
going microglial activation. 
The observed decrease in K1/k2 may be explained by BBB disruption 
in the acute phase after TBI (139). On the other hand, variations in VT in 
traumatic brain lesions and surrounding perilesional zones, particularly within 
the first month after TBI, are more difficult to interpret in the presence of an 
unchanged (R)-[11C]PK11195 BPND, as this would indicate a change in non-
specific signal during this early phase. Nevertheless, at later time points, 
when K1/k2 had normalised in traumatic brain lesions, increased (R)-
[11C]PK11195 BPND and VT values compared to those in controls were found 
in perilesional zones. Comparable to an increased (R)-[11C]PK11195 
signaling in the outer borders of stroke lesions (148), the observed late 
increase in (R)-[11C]PK11195 BPND and VT suggests the presence of 
activated microglia up to six months after TBI in the perilesional zones. 
These findings are in line with our previous work, in which a significant 
increase in both whole brain and regional (R)-[11C]PK11195 BPND values at 
six months after TBI was reported (144). 
One of the limitations of the present study is the small number of TBI 
patients. In addition, due to missing PET data at different time points, 
longitudinal changes could not be analysed. Therefore, (R)-[11C]PK11195 
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BPND, K1/k2 and VT values in both focal traumatic brain lesions and 
surrounding perilesional zones were compared to normal values in age- and 
gender- matched healthy controls. Though both administered dose of (R)-
[11C]PK11195 and its specific activity were not significantly different between 
patients and healthy controls, injected mass was. It should be noted, 
however, that the lower mass of (R)-[11C]PK11195 given to TBI patients 
should, if anything, have resulted in a lower, not higher, level of specific 
binding than seen in healthy controls. 
The main reason for evaluating microglia activation in perilesional 
zones is the fact that these areas are specific targets for preventing 
secondary injury. Conventional T1-weighted MR scans, used for co-
registration purposes, were used to define traumatic brain lesions and 
perilesional zones; the latter without any visible signs of parenchymal 
damage. Clinical reading of these MR scans showed less extensive brain 
damage in TBI patients than (R)-[11C]PK11195 PET, indicating that (R)-
[11C]PK11195 may be a sensitive marker for neuronal damage and, more 
specifically, BBB disruptions in the acute stage after TBI. As more advanced 
MR techniques, such as quantitative diffusion-tensor tractography, are able 
to show posttraumatic abnormalities in several association tracts in TBI 
patients with normal findings on conventional MR imaging (149), novel 
multimodality imaging approaches (e.g. PET/MR) could contribute in an 
improved therapeutic management and better outcomes in TBI patients. 
The complex neuroinflammatory cascade and BBB breakdown are 
hallmarks in the pathophysiology of TBI and thus represent potential 
therapeutic targets. An increase in (R)-[11C]PK11195 BPND after TBI in 
perilesional zones reflects on-going and possibly preventable, progressive 
neuronal damage. Molecular neuroimaging methods may provide increased 
insight into the complexities of brain injury, and cognitive and 
neurobehavioral recovery. Multimodality neuroimaging might be possible to 
demonstrate underlying neuropathology that affects outcome. At present, 
PET in TBI is still of limited clinical use because of complex logistics and 
infrastructural set-up, together with its associated high costs. From a 
scientific point of view, however, (R)-[11C]PK11195 PET is a sophisticated, 
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molecular imaging technique, which could contribute to the growing 
knowledge of secondary injury mechanisms in all kinds of CNS diseases, 
including TBI. In this context, PET research in TBI patients may aid in the 
development of more effective treatments in the future. 
 
Conclusions 
Changes in (R)-[11C]PK11195 kinetics reflect early posttraumatic microglia 
activation and/or macrophage influx in traumatic brain lesions, together with 
disruption of BBB integrity. Long-term increased (R)-[11C]PK11195 BPND in 
perilesional zones indicates on-going microglial activation, stressing the 
importance of prevention and treatment of secondary injury in the 
management of severe TBI patients. 
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General discussion 
This thesis provides novel insights into the neuroinflammatory cascade after 
traumatic brain injury (TBI). A central theme is reserved for activated 
microglia, the key players in posttraumatic neuroinflammation.  
 
Rationale of this thesis 
TBI remains a major public health problem worldwide. Over recent years 
there has been increased public awareness of the enormous impact of the 
dramatic long-term consequences of TBI, affecting not only the individual 
patient, but also society as a whole (1, 150, 151). Over the last decades, 
substantial progress has been made in our knowledge of the brain’s 
response to external mechanical forces, essential for a better understanding 
of the pathophysiological processes which result in secondary brain damage 
after trauma (106, 152, 153). 
The concept that TBI is not a simple event causing damage to the 
brain due to external forces, but a complex entity in which ongoing 
pathophysiological processes, influenced by multiple internal and external 
factors, determine the final outcome, is nowadays widely accepted (17, 154). 
Continuous and reliable information on all aspects of the complex 
biochemical processes, and early recognition and treatment of the symptoms 
leading to subsequent additional brain damage, seems crucial to improve the 
neurological outcome of TBI patients (155, 156). Current research, therefore, 
focuses on the cascades induced by TBI, such as excitotoxicity, metabolic 
derangements, neuroinflammation and other phenomena, which all have 
been included in the term ‘tertiary injuries’ (17, 106). With increasing 
awareness that the central nervous system (CNS) is not an immunologically 
privileged site, but is significantly affected by neuroimmunological sequelae 
after TBI, the focus of research in the field of TBI has switched to exploring 
the neuroinflammatory cascade after TBI (17, 157). 
In the acute neuroinflammatory response following TBI, the brain is 
more susceptible to effects of systemic insults such as hypotension, hypoxia, 
hyperthermia and metabolic derangements (158-160). This posttraumatic 
neuroinflammatory response involves two components: a cellular component 
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which comprises activation of resident glial cells, microglia, astrocytes, and 
infiltration of blood leukocytes, and a second component regarding secretion 
of immune mediators (161). These two components cannot be seen 
separately in the complex state of neuroinflammation after TBI. The first part 
of this discussion focuses on the secretion of immune mediators, in particular 
interleukin (IL)-1 ß and IL-6, the cellular component of the neuroinflammatory 
reponse, and the dual role of microglia activation after TBI, whereas the 
second part refers to positron emission tomography (PET) scanning 
techniques and its opportunities and limitations.  
 
Secretion of immune mediators 
From the moment of primary injury, transmigration of leucocytes results in 
microglia activation. Apart from infiltrating peripheral immune cells, a massive 
release of inflammatory cytokines, chemokines and adhesion molecules is 
initiated by activated microglia (9, 11, 17, 162). As a consequence, multiple 
cellular, metabolic and immune pathways are activated. In the cascades that 
follow, two essential cytokines in the cytotoxic pathways after TBI, IL-1 ß and 
IL-6, have been extensively studied in TBI research. IL-1 β elicits biological 
responses in a large number of cell types and has been implicated as a 
major inflammatory mediator in pathological conditions. Many of the actions 
of this particular cytokine have a direct effect on the CNS (163). The cytokine 
IL-6 has been shown to possess both pro- and anti-inflammatory properties 
in brain tissue. IL-6 could be of critically diagnostic value in determining 
whether the brain responds in a pro- or anti-inflammatory manner (161, 164). 
In exploring the component of secretion of immune mediators, we focused on 
cytokine release in extracellular fluid (ECF). 
Cerebral microdialysis is a sophisticated, widely used method in both 
clinical and preclinical settings, measuring substrates in the ECF. Before 
starting our experiments in recovering cytokines using microdialysis, we 
encountered a number of inherent methodological difficulties. First, because 
of the large molecular size of cytokines, we had to look for a microdialysis 
catheter with a relatively high molecular weight cut-off. A commercially 
available polyether sulphone (PES) microdialysis catheter met our criteria, 
though recovery characteristics for cytokines were not defined. Because 
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extraction efficiency, defined as the concentration of the substrate in the 
dialysate divided by the concentration in the ECF (57), is a key concept in 
cerebral microdialysis, we started performing in vitro experiments. In these 
experiments, we experienced that, without adding serum albumin to saturate 
non-specific binding to plastics and other materials, extraction efficiency was 
nearly zero. Our results suggest that the release of proinflammatory IL-6 is 
preceded by a peak release of IL-1ß.  (chapter 2). 
Despite promising preliminary results, there were a number of reasons 
why we did not continue measuring ECF cytokines using cerebral 
microdialysis in human TBI. First, because of the large pore size of the 
microdialysis catheter, potential net outflow of the dialysate over the 
membrane into the local environment of the microdialysis catheter could 
affect the chemical composition of ECF and thereby final results. This major 
concern is confirmed by a sophisticated electron microscopy study in which a 
precise inspection at the ultrastructure of the microdialysis membranes 
showed that, apart from cellular debris in the pores, the 100 kDa catheter 
possessed multiple large cavities (165). Furthermore, the same group found, 
in their study focusing on the cytokine response to human TBI, variable fluid 
recovery, defined as the volume of fluid collected in the vial as percentage of 
the fluid pumped into the microdialysis catheter. In addition, 3.7% of the 
crystalloid-perfused and 2.8% of the microdialysis catheters perfused with a 
3.5% human albumin solution recovered minimal fluid (166). Negative fluid 
recovery implies loss of perfusion fluid into the ECF, whereas positive fluid 
recovery can be interpreted as fluid extraction from the ECF into the 
dialysates. 
Another concern we had in resuming our cerebral microdialysis 
studies in man is the potential confounder that the microdialysis catheter 
itself could give rise to a local neuroinflammatory response and thereby 
disturb the actual cytokine release provoked by the head injury. The above-
mentioned concern is a key issue within the microdialysis literature. In a 
recent human TBI study, no cytokine peak was found after insertion of the 
microdialysis catheter (166), though other studies have shown blood-brain 
barrier (BBB) disruptions and a transformation of the microenvironment as a 
consequence of a penetrating injury of the microdialysis catheter (167, 168). 
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As previously mentioned, our experimental series suggest a prior release of 
the proinflammatory IL-1ß and a subsequent peak release of IL-6. The 
question whether increased IL-1ß concentrations in the ECF initiate release 
of IL-6, or an IL-6 peak is slowing down release of IL-1ß, remains 
unanswered. Above all, no significant higher cytokine peak release was 
found in the TBI rats (chapter 2). 
 
Cellular component of neuroinflammation 
Microglia serve as the resident mononuclear phagocytes of the brain and are 
highly heterogeneous within the healthy brain. They exhibit multiple 
morphological phenotypes and multiple functional profiles, depending on their 
environment (169-171). Considering the heterogeneity of human TBI, we 
designed a study in which we combined translocator protein (TSPO) imaging 
and glutamate release in ECF in the acute phase after experimental TBI. 
Activated microglia express a number of neurotransmitter receptors, of which 
the glutamate receptor reflects excitotoxicity. 
In a pilot study we found a significant acute increase in glutamate 
concentrations in ECF and ongoing (R)-[11C]PK11195 binding (chapter 3). 
We could not answer the following questions: Is the initial peak release of 
glutamate responsible for initiating microglia activation? To what extent is 
there a correlation between microglia activation and the release of excitatory 
amino acids (EAA) in time? And even more interestingly, looking at both 
studies together, in what way are activated microglia, release of cytokines 
and fluctuations in EAA concentrations, affected by each other? In solving 
these questions, a significant step forward can be made towards better 
understanding of posttraumatic sequelae. 
 
The duality of microglia activation 
The dual role of activated microglia, the primary mediators of the CNS’s 
innate immune defence system, is under scrutiny. Activated microglia, 
integral to the posttraumatic neuroinflammatory response, release a number 
of factors with both detrimental as well as beneficial effects (172-174). The 
dynamics of microglia fascinate many scientists, not only working in the field 
of TBI, but in a whole range of neuroinflammatory diseases. One the one 
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hand, microglia can be seen as guards, who continuously are exploring their 
microenvironment for noxious agents and injurious processes (175). Once 
activated, microglia produce a number of neuroprotective anti-inflammatory 
cytokines and neurotrophic factors (176-178), resulting in down-regulation of 
the expression of molecules associated with antigen presentation and the 
release of pro-inflammatory cytokines, chemokines, nitric oxide and 
superoxide free radicals (173, 176, 179-184). On the other hand, detrimental 
responses of activated microglia induce neuronal cell death and apoptosis (9, 
11, 40, 185-187). 
In chapter 5 we describe that a prolonged and widespread increase in 
(R)-[11C]PK11195 at six months in moderate to severe TBI patients is 
indicative of diffuse neuronal damage. These widespread pathological 
changes, without visible structural brain damage on MRI, underline the 
concept of TBI being a widespread brain disease with ongoing 
pathophysiological mechanism throughout time. 
In the perilesional zones surrounding traumatic brain lesions, we also 
found a prolonged increase in (R)-[11C]PK11195 binding (chapter 6). The 
perilesional zones, susceptible to additional brain damage (188, 189) could 
make the difference in the final outcome if protected properly. Ideally, in 
bringing above-mentioned studies together, future TSPO receptor studies 
using PET in TBI patients, should evaluate the efficacy of neuroprotective 
treatment strategies, focusing on these perilesional zones as therapeutic 
targets. In this way, the pressing question whether, and how, the 
neuroinflammatory cascades may be modulated could be elucidated. 
 
(R)-[11C]PK11195 PET imaging in TBI patients 
Where other neuroimaging techniques provide precise anatomical 
localization and neuronal activity, brain PET receptor studies, with promising 
novel radioligands, provide a unique opportunity to detect in vivo 
neuroinflammatory changes at different stages after trauma (15, 190). When 
we started our human series, (R)-[11C]PK11195 PET studies had been 
performed in a wide spectrum of neuroinflammatory brain diseases other 
than TBI (15). Although TBI cannot be seen as a pure neuroinflammatory 
entity, disturbances in BBB are likely immediately after trauma, resulting in a 
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potential increased K1/k2 variability. The use of a simplified reference tissue 
model (SRTM) could lead to an overestimation of specific (R)-[11C]PK11195 
binding. Therefore we also performed simulation studies (chapter 4). Results 
of this study stress the importance of recognizing that in the acute phase 
after TBI, (R)-[11C]PK11195 studies should only be analysed using plasma 
input models. Furthermore, as BBB disruptions are not unique for TBI, K1/k2 
variability can be a potential confounder in (R)-[11C]PK11195 analyses if 
reference tissue approaches are used. 
 
Limitations of PET imaging in TBI patients 
Some technical notes and limitations have to be mentioned concerning PET 
imaging in TBI patients. Before starting the studies described in this thesis, 
we set up a protocol in which (R)-[11C]PK11195 PET scanning was 
scheduled within four hours after severe brain trauma. Goal of this research 
was to visualize and quantify (R)-[11C]PK11195-uptake in order to measure 
and evaluate posttraumatic neuroinflammation in the ultra-acute phase after 
TBI. Favourable in-hospital conditions, e.g. protocol-trained paramedics, 24/7 
availability of physician-based emergency medical services, relatively short 
pre-hospital run times (191) and an on-site cyclotron, provided us with the 
unique opportunity to monitor (R)-[11C]PK11195 binding profiles in the ultra-
acute phase after severe TBI. Unfortunately, we did not succeed in enrolling 
patients within the initial two years in which the protocol was open. The main 
reason for failure was an insufficient number of patients presented to the 
emergency department within normal office hours combined with the lack of 
informed consent within the short time frame after trauma. Secondly, 
unstable clinical conditions of the patients frequently required immediate 
surgical intervention. PET scanning in the ultra-acute phase after TBI might, 
however, be possible in the near future when both Amsterdam university 
hospitals decide to concentrate all severe brain trauma patients in one 
facility, the University Medical Center Amsterdam. 
When scanning severe TBI patients in the acute phase they are strictly 
dependent on intensive monitoring and often they are still on an artificial 
ventilator. In these cases, in order to guarantee patient safety during 
transport to the PET facility and during PET scanning itself, the entire 
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procedure must be attended by an experienced intensive care specialist. For 
this reason, our PET camera is situated in an intensive care unit setting 
accommodated with all necessary equipment. As mentioned before, it is 
essential to use fully quantitative methods for data acquisition and analysis to 
reliably assess (R)-[11C]PK11195 binding, for which an indwelling artery 
catheter is needed (139). 
Apart from logistical and safety matters, an important methodological 
issue in PET scanning is the effect of head motion. Total scanning time is 
often too long for TBI patients. Not only in the acute phase, but also in the 
sub-acute and chronic phase, head movement artefacts due to incorrigible 
restlessness of the patient are the main reason of technical failure of PET 
scanning in (semi-)conscious TBI patients. Head motion may result in over- 
or underestimation of radioligand uptake.  
 
Novel TSPO receptor ligands 
The potential useful clinical application of (R)-PK11195 is based on three 
observations: 1) limited to glial cells, low levels of TSPO, an 18 kDa 
hydrophobic outer mitochondrial membrane protein (192), are present in 
unaffected brain (193); 2) in CNS injury, in vivo (R)-PK11195 binding is 
predominantly limited to activated microglia; and 3) labelled with 11C, 
PK11195 can be used as a radioligand (142). The finding that a dramatic 
increase in TSPO levels can be found in response to CNS damage has led to 
the proposed use of TSPO expression as a marker of brain injury and repair 
(23). Nevertheless, a relatively high level of non-specific binding and low 
signal-to-noise ratio complicates interpretation of (R)-[11C]PK11195 signals. 
After completing our series, an increasing number of promising 
second generation TSPO receptor ligands with more favourable binding 
profiles, such as [11C]DAA1106, [11C]DPA713, [11C]PBR01, [11C]PBR28, 
[11C]DAC and [11C]CLINME have been synthesized. The radioligand 
[11C]DAA1106 binds selectively to TSPO with a higher affinity than (R)-
[11C]PK11195 (194). In a rat model of TBI, [11C]DAA1106 showed higher 
affinity to microglia compared to (R)-[11C]PK11195 suggesting that 
[11C]DAA1106 may represent an even better ligand for in vivo PET imaging of 
microglia activation in TBI (195). In a rat model of herpes encephalitis, 
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Doorduin et al. found that [11C]DAA1106 showed high and specific ex vivo 
uptake in the encephalitic rat brain. In vivo, however, neuroinflammation 
could not be demonstrated using [11C]DAA1106 PET. Due to rapid tissue 
uptake, slow tissue clearance and low plasma activity, [11C]DAA1106 
quantification was less than optimal (196). The same group used this model 
in another series in which the TSPO radioligand pyrazolopyrimidine 
[11C]DPA-713 had lower background binding and therefore appears to be 
more suitable than (R)-[11C]PK11195 for visualizing mild inflammation. 
[18F]DPA-713 showed low non-specific binding, but also lower specific 
binding, though it seems to have potential to evaluate different aspects of 
neuroinflammation (92). Due to high specific binding and low lipophilicity, 
studies performed using [11C]PBR01 and [11C]PBR28 showed promising first 
results in rat and monkey brain (197). In humans however, due to a 10-fold 
lower affinity for [11C]PBR28, it appeared that 10-14% showed no binding at 
all (198, 199). In a study performed in kainic acid lesioned rats, [11C]DAC 
TSPO binding was increased significantly in the affected striatum. 
Furthermore, [11C]DAC showed good contrast between lesioned and non-
lesioned striatum, and it showed high in vivo specific binding to TSPO in 
injured rat brain (200). A potential alternative to (R)-[11C]PK11195 in in vivo 
imaging of microglia activation is  [11C]CLINME. In a rat model of local acute 
neuroinflammation, uptake levels in the lesions were the same for both 
tracers, but due to a lower uptake in the unaffected side of the brain, 
[11C]CLINME exhibited a higher contrast than (R)-[11C]PK11195 (201). 
Although (R)-[11C]PK11195 is well-characterized and widely used in 
quantification of microglia activation in human CNS disease, promising novel 
TSPO radioligands with more optimal binding profiles, e.g. increased signal-
to-noise ratio, high specific and low non-specific binding, might be superior to 
(R)-[11C]PK11195 in TSPO imaging and suitable as new biomarkers in 
evaluating microglia activation after human TBI in the very near future. 
Though, apart from PK11195, in all TSPO radioligands in clinical use 
(PBR28, PBR06, DAA1106, PBR111, DPA173) recognize high-affinity, low-
affinity, and mixed-affinity binders in brain tissue post-mortem. Using these 
radioligands, differences in PET signal across subjects cannot be interpreted 
directly as differences in receptor density. Varying affinity for TSPO 
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radioligands will be a challenge for quantitative PET binding studies and 
knowledge of binding status will be required to correctly quantify TSPO 
expression with PET (199, 202). 
 
Future perspectives 
In view of the enormous impact of TBI in all its facets, the need for effective 
therapies still remains. Until now, it is unclear whether neuroinflammation is a 
reactive process or whether there is an active effect on disease progression. 
Future studies focusing on posttraumatic neuroinflammation are of great 
importance to rule out whether microglia activation is beneficial or detrimental 
to the brain. Or could it be that activated microglia themselves are a victim of 
the neuroinflammatory cascade? In answering these questions, novel TSPO 
receptor ligands with high specific binding potentials and favourable signal-
to-noise ratios will open new possibilities in evaluating these different aspects 
of microglial activation, eventually resulting in better understanding of the 
complex neuroinflammatory cascade following TBI. In solving these 
questions, a significant step forward can be made in better understanding of 
the microglial cellular responses and secretion of immune mediators after 
TBI. Finally, identification of evidenced-based treatment strategies based on 
preventing the detrimental effects of microglia activation and promoting 
potential beneficial features, is the ultimate goal in this field of research for 
the benefit of a better outcome of future TBI patients. 
 CHAPTER 8 
Summary 
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Summary 
Chapter 1 provides a general introduction for this thesis entitled “Activated 
Microglia After Traumatic Brain Injury, The Neuroinflammatory Mastermind”. 
According to the World Health Organization (WHO), traumatic brain injury 
(TBI) will surpass many diseases as the major cause of death and disability 
by the year 2020 (1). Besides emotional, financial and social burden to the 
patients, their families and their social network, the burden of mortality and 
morbidity that TBI imposes on society, makes this heterogeneous disease 
with respect to cause, pathology, severity and prognosis, a pressing public 
health and medical problem. 
Over the last decades, substantial progress has been made in a better 
understanding of the pathophysiological processes after TBI. It is nowadays 
widely accepted that TBI is not just a simple event but a complex entity with 
ongoing pathophysiological mechanisms (106, 152, 153). Posttraumatic 
neuroinflammatory sequelae involves two components: a cellular component, 
including microglia activation, and a second component regarding secretion 
of immune mediators (161). Microglia express a dual and opposing role after 
activation under pathological conditions. Probably depending on the type of 
signal emitted by the neuron in distress, activated microglia are the initiators 
of an endogenous auto-protective mechanism in order to rescue the neuronal 
cell (18), or turn out to be the key role player in initiating and continuing the 
acute posttraumatic neuroinflammatory response, characterized by a 
massive release of inflammatory cytokines, including interleukin (IL)–1β and 
IL-6, chemokines and complement activation proteins (17). 
Because of the heterogeneity of the disease, animal models of TBI, 
classified in focal and diffuse brain injury, provide the opportunity to study 
posttraumatic pathophysiological mechanisms under stable and controlled 
environmental conditions, minimizing variability with regard to the mechanism 
of injury. We used the radionuclide (R)-[11C]PK11195, that binds to the 
microglial translocator protein (TSPO), and positron emission tomography 
(PET) to measure microglia activation. As a reflection of the posttraumatic 
neuroinflammatory response, we monitored the release of IL-1β and IL-6 and 
excitatory amino acids (EAA) using cerebral microdialysis, a neuromonitoring 
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technique based on diffusion of substances from the extracellular fluid (ECF) 
through a semipermeable membrane into a perfusion fluid. 
In chapter 2 we established, as a proof of principle, extraction 
efficiency of IL-1ß and IL-6 by an in vitro microdialysis-perfusion system, 
using a polyether sulfon (PES) microdialysis probe, especially developed for 
recovery of macromolecules such as cytokines. To explore the feasibility of 
cytokine extraction from the ECF using cerebral microdialysis and to 
elucidate the temporal profile of extracellular IL-1ß and IL-6, rats were 
exposed to focal brain injury or sham procedure. It appeared that cytokine 
extraction was feasible in vitro after adding a carrier protein and that both IL-
1ß and IL-6 was detectable using cerebral microdialysis. Our findings 
suggest that IL-1ß release precedes a gradual increase in expression of IL-6. 
In chapter 3 we investigated the posttraumatic microglia activation 
over time related to the release of glutamate. Rats underwent three 
sequential dynamic (R)-[11C]PK11195 PET scans, at baseline and one and 
ten days after TBI. Glutamate in the ECF was measured using cerebral 
microdialysis in the acute posttraumatic phase and brains were processed for 
histopathology and (immuno)-histochemistry. We found that ten days after 
TBI, (R)-[11C]PK11195 binding was significantly increased in TBI rats 
compared with both baseline values and sham controls. This increased 
cerebral uptake of (R)-[11C]PK11195 followed a significant acute 
posttraumatic increase in ECF glutamate levels. Post mortal, significant 
differences were found between TBI and sham in representative examples of 
brain tissue stained for ED-1 (positive cells are highly activated microglia 
and/or macrophages), OX-6 (marker of activated microglia), GFAP 
(expressed in astrocyte cells), Perl's (indicative of haemorrhages), and 
Fluoro-Jade B (indicative of degenerating neurons). 
In most studies (R)-[11C]PK11195 binding has been quantified using 
reference tissue approaches. The purpose of the study described in chapter 
4 was to assess the validity of the simplified reference tissue model (SRTM) 
for analyzing (R)-[11C]PK11195 studies in TBI, where blood-brain barrier 
(BBB) disruptions are likely. Dynamic (R)-[11C]PK11195 scans were acquired 
at three time points after TBI. Plasma input derived binding potential 
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(BPNDPI), volume of distribution (VT) and K1/k2, and SRTM derived BPNDSRTM 
were obtained. Simulations were performed to assess effects of varying 
K1/k2. We conclude that early after TBI, (R)-[11C]PK11195 studies should be 
analysed using plasma input models. 
The objective of the study described in chapter 5 was to measure (R)-
[11C]PK11195 binding as an indirect marker of neuronal damage after TBI. 
We therefore acquired dynamic (R)-[11C]PK11195 PET scans in TBI patients, 
six months after trauma. Supervised cluster analysis (SVCA4) was used to 
generate an appropriate reference tissue input. We found an increased whole 
brain binding of (R)-[11C]PK11195 in TBI patients compared to healthy 
controls and regional analysis indicated that increased (R)-[11C]PK11195 
binding was widespread over the brain, indicative of diffuse neuronal 
damage. 
In chapter 6 we assessed longitudinal changes in microglia activation 
in traumatic brain lesions and surrounding perilesional zones. Therefore, we 
performed fully quantitative (R)-[11C]PK11195 PET-scans with arterial 
sampling were performed in TBI patients, at three different time points: 7-10 
days, one and six months after trauma. (R)-[11C]PK11195 BPND, K1/k2 and 
VT of traumatic brain lesions and surrounding perilesional zones were 
measured using a validated tracer kinetic model with metabolite-corrected 
plasma input function. Traumatic brain lesions were defined on magnetic 
resonance imaging scans. In the acute stage (7-10 days) in traumatic brain 
lesions and six months after TBI in perilesional zones, significantly higher 
(R)-[11C]PK11195 BPND values were found compared to healthy controls. 
Increased (R)-[11C]PK11195 BPND in perilesional zones after TBI indicates 
microglia activation and/or macrophage influx in these regions. Prolonged 
increase in (R)-[11C]PK11195 binding in perilesional zones points to long-
term posttraumatic microglia activation, which may be a therapeutic target for 
future neuroprotective studies. 
Finally, the results of this thesis are discussed in chapter 7. (R)-
[11C]PK11195 PET imaging in TBI patients has some logistical and safety 
matters and methodological limitations, though, this neuroimaging technique 
provides a unique opportunity to monitor neuroinflammation in vivo, in time. 
Summary 95 
 
Promising novel TSPO radioligands in TSPO imaging are suitable as new 
biomarkers in evaluating microglia activation after TBI in the very near future. 
Future research in the field of TBI should focus on the dual and opposing role 
of activated microglia to mastermind the complex neuroinflammatory 
cascades in this, in many ways, devastating disease. 
 
 CHAPTER 9 
Samenvatting 
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Samenvatting 
Hoofdstuk 1 is een algemene inleiding van dit proefschrift met als titel: 
“Activated Microglia After Traumatic Brain Injury, The Neuroinflammatory 
Mastermind”. Volgens de Wereldgezondheidsorganisatie (WGO) zal 
traumatisch hoofd-hersenletsel de belangrijkste oorzaak zijn van overlijden 
en handicap in het jaar 2020 (1). Naast emotionele, financiële en sociale 
beperkingen voor de patiënt, zijn familie en omgeving, legt overlijden en 
ziekte als gevolg van traumatisch hoofd-hersenletsel, een heterogene ziekte 
wat betreft oorzaak, pathologie, ernst en prognose, een grote druk op het 
gezondheidszorgsysteem. 
In de afgelopen decennia is er een aanzienlijke vooruitgang geboekt in 
een beter begrip van de pathofysiologische processen na traumatisch hoofd-
hersenletsel. Het is tegenwoordig algemeen aanvaard dat traumatisch hoofd-
hersenletsel niet een alleen een enkelvoudige gebeurtenis is, maar een 
complexe entiteit met voortdurende pathofysiologische mechanismen (106, 
152, 153). Posttraumatische neuroinflammatoire gevolgen kunnen worden 
onderverdeeld in twee componenten: een cellulaire component, waaronder 
microglia activering, en een component met het vrijkomen van immuun 
mediators (161). Geactiveerde microglia hebben een tweeledige en 
tegenovergestelde rol onder pathologische condities zoals traumatisch 
hoofd-hersenletsel. Enerzijds zijn het de initiators van een intern auto-
protectief mechanisme, met als doel herstellen van de hersencel (18). 
Anderzijds nemen ze een sleutelpositie in wat betreft het initiëren en 
continueren van een acute posttraumatische neuroinflammatoire respons, 
gekarakteriseerd door een massaal vrijkomen van inflammatoire cytokinen, 
waaronder interleukin (IL)–1β and IL-6, chemokinen en complement activatie 
eiwitten (17). 
Vanwege het feit dat traumatisch hoofd-hersenletsel een heterogene 
ziekte is zijn dierexperimentele modellen nodig, onderverdeeld in focaal en 
diffuus hersenletsel, om posttraumatische pathofysiologische mechanismen 
onder stabiele en gecontroleerde omstandigheden te onderzoeken. Wij 
hebben gebruik gemaakt van de radionuclide (R)-[11C]PK11195, welke bindt 
aan de microgliale translocator eiwit (TSPO) en positron emissie tomografie 
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(PET) om microglia activatie te meten. Als een reflectie op de 
posttraumatische neuroinflammatoire respons hebben we gebruik gemaakt 
van cerebrale microdialyse. Cerebrale microdialyse is een neuromonitoring 
techniek gebaseerd op diffusie van stoffen in de extracellulaire vloeistof 
(ECF) over een semi-permeabele membraan in een perfusie vloeistof. 
In hoofdstuk 2 hebben we de extractie-efficiëntie van IL-1ß en IL-6 
bepaald via een in vitro microdialysis-perfusie-systeem en een polyether 
sulfon (PES) microdialyse katheter. Een PES microdialyse katheter is 
speciaal geschikt voor onderzoek naar macromoleculen zoals cytokinen. Uit 
dit onderzoek bleek dat het mogelijk was om cytokinen in vitro te extraheren 
met behulp van microdialyse na het toevoegen van een drager eiwit.  Om 
een indruk te krijgen van het profiel in de tijd van IL-1ß en IL-6 in de ECF, 
werden ratten blootgesteld aan focaal traumatisch hoofd-hersenletsel of 
schijn procedure. Hieruit bleek dat zowel IL-1ß als IL-6 in de ECF 
aantoonbaar was met behulp van cerebrale microdialyse in vivo. Onze 
bevindingen waren dat het vrijkomen van IL-1ß voorafgegaan wordt door een 
geleidelijke toename in expressie van IL-6. 
In hoofdstuk 3 onderzochten we de posttraumatische microglia 
activering in de tijd gerelateerd aan het vrijkomen van glutamaat, een 
belangrijke stimulerende neurotransmitter. Ratten ondergingen drie 
opeenvolgende dynamische (R)-[11C]PK11195 PET scans. De eerste 
(uitgangs)scan werd gemaakt voor het hoofd-hersenletsel. De tweede en 
derde scan werden gemaakt op de eerste en tiende dag na het onderzoek. 
Glutamaat in de ECF werd gemeten met behulp van cerebrale microdialyse 
in de acute posttraumatische fase. De hersenen werden verwerkt voor 
histopathologisch onderzoek en (immuno)-histochemie. We vonden dat tien 
dagen na traumatisch hoofd-hersenletsel de (R)-[11C]PK11195 binding 
significant verhoogd was in ratten welke traumatisch hoofd-hersenletsel 
hadden ondergaan in vergelijking met zowel de waarden van de 
uitgangsscan en de controle groep. Deze verhoogde cerebrale opname van 
(R)-[11C]PK11195 volgde op een significant acute posttraumatische toename 
ECF glutamaat. Postmortaal vonden we significante verschillen tussen de 
ratten die traumatisch hoofd-hersenletsel hadden ondergaan en de controle 
100 Chapter 9 
 
ratten in representatief hersenmateriaal voor ED-1 (positieve cellen zijn 
geactiveerde microglia en/of macrofagen), OX-6 (marker van geactiveerde 
microglia), GFAP (komt vrij uit astocyten), Perl's (indicatief voor bloeding) en 
Fluoro-Jade B (indicatief voor neuronale degeneratie). 
In de meeste studies wordt (R)-[11C]PK11195 binding gekwantificeerd 
met behulp van een reference tissue model. Het doel van het onderzoek 
zoals beschreven in hoofdstuk 4 was het de validatie van een simplified 
reference tissue model (SRTM) voor het analyseren van (R)-[11C]PK11195 
PET studies naar traumatisch hoofd-hersenletsel, waar verstoringen van de 
bloed-hersenbarrière (BBB) plausibel zijn. Dynamische (R)-[11C]PK11195 
scans werden verricht op drie tijdstippen na traumatisch hoofd-hersenletsel. 
Plasma input (PI) binding potential (BPNDPI), volume of distribution (VT), 
K1/k2, en BPNDSRTM werden bepaald. Simulaties werden uitgevoerd om de 
effecten van verschillende K1/k2 na te bootsen. We concluderen dat vroeg na 
traumatisch hoofd-hersenletsel (R)-[11C]PK11195 studies moeten worden 
geanalyseerd met behulp van PI modellen. 
Het doel van het onderzoek zoals beschreven in hoofdstuk 5 was het 
onderzoeken van de mate van (R)-[11C]PK11195 binding als een indirecte 
marker voor neuronale schade na traumatisch hoofd-hersenletsel. 
Dynamische (R)-[11C]PK11195 PET scans werden verricht van patiënten die 
een traumatisch hoofd-hersenletsel hadden ondergaan, zes maanden na het 
ongeval. Supervised cluster analysis (SVCA4) werd gebruikt voor het 
genereren van een referentie waarde. We vonden een toegenomen totale 
(R)-[11C]PK11195 binding in de hersenen bij patiënten met traumatisch 
hoofd-hersenletsel vergeleken met gezonde controles. Regionale analyse 
wijst uit dat dat een verhoogde (R)-[11C]PK11195 binding indicatief is voor 
diffuus neuronale schade. 
In hoofdstuk 6 bestuderen we de longitudinale veranderingen in 
microglia activatie in de traumatische laesies als ook de zone rondom deze 
laesies. Hiervoor hebben we volledig kwantitatieve (R)-[11C]PK11195 PET-
scans uitgevoerd van patiënten na traumatisch hoofd-hersenletsel op drie 
verschillende tijdstippen: 7-10 dagen, één en zes maanden na het hoofd-
hersenletsel. (R)-[11C]PK11195 BPND, K1/k2 en VT van de traumatische 
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laesies en het omliggende weefsel werden gemeten met behulp van een 
gevalideerde tracer kinetisch model met metaboliet-gecorrigeerd PI functie. 
Traumatische laesies werden gedefinieerd op magnetic resonance imaging 
van de hersenen. In de acute fase (7-10 dagen) zagen we in traumatische 
laesies en zes maanden na het trauma in het omliggende weefsel, significant 
hogere waarden (R)-[11C]PK11195 in vergelijking met gezonde controles. 
Verhoogde (R)-[11C]PK11195 in het omliggende weefsel na traumatisch 
hersenletsel duidt op microglia activering en/of macrofagen toestroom in 
deze regio's. De lange termijn verhoogde (R)-[11C]PK11195 binding in het 
omliggende weefsel duidt op lange termijn posttraumatische activering van 
microglia welke in de toekomst welllicht een therapeutisch doel voor 
toekomstige neuroprotectieve studies zou kunnen zijn. 
Tot slot worden de resultaten van dit proefschrift bediscussieerd in 
hoofdstuk 7. Hoewel (R)-[11C]PK11195 PET imaging in patiënten met 
traumatisch hoofd-hersenletsel enkele beperkingen kent wat betreft logistiek, 
patiëntveiligheid en enkele methodologische valkuilen, biedt deze 
neuroimaging techniek een unieke gelegenheid om de infammatoire reactie 
in de hersenen in vivo en in de tijd te kunnen onderzoeken. Veelbelovende 
nieuwe TSPO radioliganden in TSPO onderzoek zijn geschikt als nieuwe 
biomarkers bij de evaluatie van microglia activering na traumatisch hoofd-
hersenletsel in de zeer nabije toekomst. Toekomstig onderzoek op het 
gebied van traumatisch hoofd-hersenletsel zal zich moeten richten op de 
tweeledige en tegenovergestelde rol van geactiveerde microglia om een 
beter inzicht te verkrijgen van de complexe neuroinflammatoire cascades van 
deze in vele opzichten verwoestende ziekte. 
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List of abbreviations 
aCSF artificial cerebral spinal fluid 
ASDH acute subdural hematoma 
BBB  blood-brain barrier 
BSA  bovine serum albumin 
BP  binding potential 
CSF  cerebrospinal fluid 
CCI  controlled cortical impact 
CNS central nervous system 
CSF  cerebrospinal fluid 
CT  computed tomography 
DAI  diffuse axonal injury 
EAA  excitatory amino acid 
ECF extracellular fluid 
EDH extradural hematoma 
ELISA Enzym-Linked Immunosorbent Assay 
GCS  Glasgow Coma Scale 
GOSE  extended Glasgow Outcome Scale 
GFAP  glial fibrillary acidic protein 
HE  haematoxylin and eosin 
HPE  high performance ELISA 
HRRT  High Resolution Research Tomograph 
IDID  image-derived injection dose 
IL  interleukin 
LFP lateral fluid percussion 
LSO single lutetium oxy-orthosilicate 
MD microdialysis 
MFP midline fluid percussion 
MR magnetic resonance 
NMDA N-methyl-D-aspartate 
OSEM 3-D three dimensional ordered set expectation maximization 
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PET  positron emission tomography 
PES  polyether sulfon 
PI plasma input 
SD Sprague-Dawley 
SVCA4 supervised cluster analysis 
SRTM simplified reference tissue model 
SUV standard uptake volume 
TAC time activity curve 
TBI  traumatic brain injury 
TNF  tumor necrosis factor 
TSPO  translocator protein 
VOI  volume of interest 
VT volume of distribution 
WGO Wereldgezondheidsorganisatie 
WHO World Health Organization 
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